var title_f32_24_33152="Naphazoline: Drug information";
var content_f32_24_33152=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naphazoline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/53/29523?source=see_link\">",
"       Naphazoline (nasal): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/60/15300?source=see_link\">",
"       Naphazoline (ophthalmic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9681 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33152=[""].join("\n");
var outline_f32_24_33152=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/53/29523?source=related_link\">",
"      Naphazoline (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/60/15300?source=related_link\">",
"      Naphazoline (ophthalmic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_24_33153="Cataracts view PI";
var content_f32_24_33153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    How cataracts affect vision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cataracts blur or dull what you see. Sometimes they also cause a glare.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Eye Institute Eye Disease Simulations.",
"     <a href=\"file://www.nei.nih.gov/health/examples/\">",
"      file://www.nei.nih.gov/health/examples/",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33153=[""].join("\n");
var outline_f32_24_33153=null;
var title_f32_24_33154="Trypsin, balsam peru, and castor oil: Drug information";
var content_f32_24_33154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trypsin, balsam peru, and castor oil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/22/22883?source=see_link\">",
"    see \"Trypsin, balsam peru, and castor oil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Granulex&reg;;",
"     </li>",
"     <li>",
"      TBC;",
"     </li>",
"     <li>",
"      Vasolex&trade;;",
"     </li>",
"     <li>",
"      Xenaderm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F177384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Protectant, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F177378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dermatologic conditions:",
"     </b>",
"     Topical: Apply a minimum of twice daily or as often as necessary",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F177379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Granulex&reg;: Trypsin 0.12 mg, balsam Peru 87 mg, and castor oil 788 mg per gram (60 g, 120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TBC: Trypsin 0.1 mg, balsam Peru 72.5 mg, and castor oil 650 mg per 0.82 mL (60 g, 120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vasolex&trade;: Trypsin 90 USP units, balsam Peru 87 mg, and castor oil 788 mg per gram (5 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xenaderm&reg;: Trypsin 90 USP units, balsam Peru 87 mg, and castor oil 788 mg per gram (30 g, 60 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F177370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not apply on fresh arterial clots.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aerosol spray: Shake can well before spraying; hold can upright ~12&rdquo; from area to be treated, and spray and coat wound rapidly (temporary stinging may occur). May be used with appropriate wet dressing if needed or wound may be left unbandaged. To remove, wash gently with water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Apply a thin film over the area being treated. May be used with appropriate dressing if needed or wound may be left unbandaged. To remove, wash gently with appropriate wound cleanser.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F177369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Granulex&reg;: Treatment of decubitus ulcers, varicose ulcers, debridement of eschar, dehiscent wounds and sunburn; promote wound healing; reduce odor from necrotic wounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vasolex&trade;, Xenaderm &reg;: Treatment of decubitus ulcers, varicose ulcers, and dehiscent wounds; promote wound healing; reduce odor from necrotic wounds",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F177389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Granulex&reg; may be confused with Regranex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F177382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Local: Temporary stinging at application site",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F177372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F177361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemoglobin deficiency: Wound healing may be retarded in the presence of hemoglobin deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Zinc deficiency: Wound healing may be retarded in the presence of zinc deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aerosol: Flammable; do not expose to high temperatures or flame.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid contact with eyes. Do not apply to fresh arterial clots.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F177373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Granulex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.12-788-87 mg/g (56.7 g): $15.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Optase External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.12-788-87 mg/g (6 g): $8.75",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F177360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trypsin may be used to debride necrotic tissue; balsam peru stimulates circulation at the wound site and may be mildly bactericidal; castor oil improves epithelialization, acts as a protectant covering and helps reduce pain",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10104 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FF084CEA57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33154=[""].join("\n");
var outline_f32_24_33154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177377\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177384\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177378\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177379\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177368\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177357\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177370\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177369\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177389\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177382\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177372\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177361\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300186\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223568\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177373\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177360\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10104\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10104|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/22/22883?source=related_link\">",
"      Trypsin, balsam peru, and castor oil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_24_33155="Oral papillomas in Cowden syndrome patient";
var content_f32_24_33155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Oral papillomas on the lips and tongue of a Cowden syndrome patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Stanich PP, Francis DL, Sweetser S. The spectrum of findings in Cowden syndrome. Clin Gastroenterol Hepatol 2011; 9:e2. Illustrations used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33155=[""].join("\n");
var outline_f32_24_33155=null;
var title_f32_24_33156="Favre Racouchot";
var content_f32_24_33156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Favre-Racouchot Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 87-year-old man, with a history of chronic sun exposure, developed prominent asymptomatic open comedones on the upper cheeks and sides of his nose.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A. Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33156=[""].join("\n");
var outline_f32_24_33156=null;
var title_f32_24_33157="Colonic adenoma cancer Light";
var content_f32_24_33157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonic adenoma with malignant transformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a colonic adenoma which has undergone malignant transformation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33157=[""].join("\n");
var outline_f32_24_33157=null;
var title_f32_24_33158="Stellate lesions II";
var content_f32_24_33158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows a stellate lesion that is characteristic of pulmonary Langerhans cell histiocytosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33158=[""].join("\n");
var outline_f32_24_33158=null;
var title_f32_24_33159="Definition and extent of resection for adenocarcinoma of the EGJ";
var content_f32_24_33159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Definition and extent of resection for type I, II, and III adenocarcinoma of esophagogastric junction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 658px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These figures represent the Siewert classification for tumors arising at the esophagogastric junction (EGJ) and the extent of the surgical resection for an EGJ adenocarcinoma, including regional lymph nodes, based upon the Siewert classification.",
"    <br>",
"     Type I adenocarcinoma is located in the distal esophagus and is resected by a subtotal gastrectomy, subtotal esophagectomy, and regional lymphadenectomy.",
"     <br>",
"      Type II adenocarcinoma arises from the cardia or the EGJ and is resected by a total gastrectomy, distal esophagectomy, and regional lymphadenectomy.",
"      <br>",
"       Type III adenocarcinoma originates in the subcardial gastric location, infiltrates the EGJ and distal esophagus from below, and is resected by a total gastrectomy, distal esophagectomy, and regional lymphadenectomy.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Based on information from: Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP. Oesphagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol 2011; 12:296.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33159=[""].join("\n");
var outline_f32_24_33159=null;
var title_f32_24_33160="Psoralen plus ultraviolet A (PUVA) photochemotherapy";
var content_f32_24_33160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/24/33160/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33160/contributors\">",
"     Elisabeth G Richard, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33160/contributors\">",
"     Warwick Morison, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/24/33160/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33160/contributors\">",
"     Craig A Elmets, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/24/33160/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33160/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/24/33160/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31513778\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoralen plus ultraviolet A (PUVA) photochemotherapy combines the administration of psoralens, a class of phototoxic plant-derived compounds, with an exposure to ultraviolet A radiation (UVA). PUVA is used for the treatment of a variety of skin diseases, including psoriasis, mycosis fungoides, eczema, vitiligo, and graft-versus-host disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    This topic will discuss the mechanism of action, treatment protocols, contraindications, adverse effects, and clinical indications of PUVA therapy.",
"   </p>",
"   <p>",
"    The use of PUVA for the treatment of specific skin conditions is discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment of psoriasis\", section on 'Ultraviolet light'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17017?source=see_link&amp;anchor=H21#H21\">",
"       \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'PUVA'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44457?source=see_link&amp;anchor=H14#H14\">",
"       \"Management of severe refractory atopic dermatitis (eczema)\", section on 'Psoralen plus UVA'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21193?source=see_link&amp;anchor=H13#H13\">",
"       \"Vitiligo\", section on 'Ultraviolet light'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of chronic graft-versus-host disease\", section on 'Psoralen ultraviolet irradiation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513814\">",
"    <span class=\"h1\">",
"     PSORALENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoralens are naturally occurring phototoxic compounds that are able to enter the cell, absorb light photons, and produce a photochemical reaction that alters the function of DNA and other cell constituents. As part of PUVA therapy, psoralens may be applied topically or taken orally.",
"   </p>",
"   <p>",
"    Psoralens are produced by a variety of plants of the Apiaceae and Rutaceae families, including fig, lime, celery, and parsnip. The medicinal properties of psoralens have been known for centuries and their use in treating vitiligo was recorded as long ago as 1550 BC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/4\">",
"     4",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Three psoralens are used for PUVA therapy (",
"    <a class=\"graphic graphic_table graphicRef83021 \" href=\"mobipreview.htm?39/27/40380\">",
"     table 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"     Methoxsalen",
"    </a>",
"    or 8-methoxypsoralen (8-MOP) is the most widely used and the only psoralen available in the United States. Trioxsalen or 4,5&rsquo;,8-trimethylpsoralen and bergapten or 5-methoxypsoralen are available in Europe and elsewhere (",
"    <a class=\"graphic graphic_figure graphicRef83609 \" href=\"mobipreview.htm?10/4/10309\">",
"     figure 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3425444\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intestinal absorption rate of psoralens depends upon the physical characteristics of the preparation, concomitant food intake, and individual factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variable absorption can impact the effect of psoralen on UVA exposure. Dissolved preparations (eg, soft gelatin capsules) are better absorbed than micronized, crystalline formulations (eg, hard gelatin capsules) and yield peak serum levels in a relatively reproducible time in all subjects (",
"    <a class=\"graphic graphic_table graphicRef83021 \" href=\"mobipreview.htm?39/27/40380\">",
"     table 1",
"    </a>",
"    ). Food intake retards and decreases the absorption of psoralens. A first-pass effect (eg, the amount of drug that is metabolized by the liver after intestinal absorption, before entering the general circulation) may be the cause of the high interindividual variability in the plasma levels achieved after a fixed dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"     methoxsalen",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In the blood, 75 to 80 percent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"     methoxsalen",
"    </a>",
"    is reversibly bound to serum albumin and is distributed to all organs. In the absence of UVA exposure, the binding is short lived and the drug is rapidly metabolized in the liver and excreted with urine as inactive metabolites. Drugs that induce cytochrome P-450 enzymes accelerate the metabolism of methoxsalen and may decrease the biologic effect of PUVA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/7,9-11\">",
"     7,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"     methoxsalen",
"    </a>",
"    after transepidermal absorption depends upon the method of application [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/12\">",
"     12",
"    </a>",
"    ]. Methoxsalen 0.15% emulsion or solution applied topically to large body areas leads to plasma levels comparable to those achieved with oral administration. In contrast, plasma levels after whole body bath PUVA treatment are very low. Bathwater-delivered psoralens are readily absorbed in the skin but are promptly eliminated without cutaneous accumulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513821\">",
"    <span class=\"h2\">",
"     Photochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoralens penetrate into the cells and intercalate between DNA base pairs in the absence of UV exposure. Upon exposure to UVA radiation, the psoralen molecules absorb photons, become chemically activated and covalently bond with DNA base pairs, producing interstrand crosslinks of the double helix (",
"    <a class=\"graphic graphic_figure graphicRef83232 \" href=\"mobipreview.htm?41/13/42198\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    DNA crosslinking suppresses DNA synthesis and mitosis and may cause cell apoptosis through the activation of the p53 pathway. Cells with sublethal damage repair the DNA through an error-prone repair process, resulting in mutagenesis and photocarcinogenesis.",
"   </p>",
"   <p>",
"    Psoralens also interact with other cell components, including mitochondria, RNA, and proteins. In keratinocyte cultures, psoralens induce mitochondrial depolarization, cytochrome",
"    <em>",
"     c",
"    </em>",
"    release, production of reactive oxygen species, and activation of proteases such as caspase-3 and -9 that are implicated in cell apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/13\">",
"     13",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513828\">",
"    <span class=\"h1\">",
"     UVA SOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wavelengths of UVA lie between 320 and 400 nm in the electromagnetic spectrum (",
"    <a class=\"graphic graphic_figure graphicRef70045 \" href=\"mobipreview.htm?15/8/15502\">",
"     figure 3",
"    </a>",
"    ). The most common sources of UVA radiation are fluorescent phototherapy light bulbs with maximum emission at 352 nm. UVA doses are measured in",
"    <span class=\"nowrap\">",
"     joules/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    <span class=\"nowrap\">",
"     (J/cm",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    most often using a photometer with a maximum sensitivity at 350 to 360 nm. Although in vivo wavelengths most efficient at activating psoralens peak at 320 to 340 nm (UVA-2 spectrum (",
"    <a class=\"graphic graphic_figure graphicRef70045 \" href=\"mobipreview.htm?15/8/15502\">",
"     figure 3",
"    </a>",
"    )), the longer wavelength emitted by the available lamps is equally effective in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Psoralen activation also occurs in the UVB spectrum.",
"   </p>",
"   <p>",
"    Although a convenient source of UVA, natural sunlight is not safe for use with psoralens because of inherent difficulties in defining the therapeutic dose and increased risk of severe phototoxic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/16\">",
"     16",
"    </a>",
"    ]. Similarly, the use of tanning beds, which have emission peaks in the range of 320 to 340 nm, may unpredictably activate psoralens with increased risk of severe erythema. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4791974\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION OF PUVA",
"    </span>",
"    &nbsp;&mdash;&nbsp;PUVA exerts its therapeutic effect through multiple mechanisms, some of which are not completely understood. Proposed mechanisms include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Inhibition of cell proliferation",
"      </strong>",
"      &ndash; Initially, the mechanism in psoriasis was believed to be the inhibition of keratinocyte proliferation. However, it is now recognized that the efficacy of PUVA in the treatment of psoriasis is also based upon its immunomodulatory properties.",
"     </li>",
"     <li>",
"      <strong>",
"       Immunosuppression",
"      </strong>",
"      &ndash; The effect of PUVA in inflammatory diseases (with or without a hyperproliferative component) is mediated by its immunomodulatory properties, including alteration of cytokine and cytokine receptor expression, lymphocyte apoptosis, functional perturbation in the types and function of antigen presenting cells, and reduced expression of adhesion molecules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/17-20\">",
"       17-20",
"      </a>",
"      ]. The effect of PUVA in the early stages of mycosis fungoides is likely related to the ability of PUVA to induce lymphocyte apoptosis in dermal infiltrates.",
"     </li>",
"     <li>",
"      <strong>",
"       Melanogenesis",
"      </strong>",
"      &ndash; PUVA stimulates melanocyte proliferation, melanogenesis, and transfer of melanosomes to keratinocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/21\">",
"       21",
"      </a>",
"      ]. This mechanism of action, while therapeutic in vitiligo, leads to hyperpigmentation as an adverse effect of PUVA in the treatment of other conditions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1377222\">",
"    <span class=\"h1\">",
"     PHOTOSENSITIVITY EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed phototoxic erythema and pigmentation are the main photosensitivity effects of PUVA treatment. The erythema intensity is proportional to the dose of psoralen and UVA radiation, although there is variability in the photosensitivity response among individuals.",
"   </p>",
"   <p>",
"    PUVA-induced erythema usually appears 36 to 48 hours after exposure to UVA radiation and peaks at 48 to 96 hours or even up to 120 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/22\">",
"     22",
"    </a>",
"    ]. Erythema occurs in 10 percent of patients. PUVA treatments are usually given 48 hours apart because daily exposure may result in severe delayed cumulative phototoxicity. Excessive doses of PUVA may induce severe erythema with blistering, intense pruritus, or skin pain. (See",
"    <a class=\"local\" href=\"#H31513954\">",
"     'Short-term adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    PUVA-induced pigmentation may occur in the absence of erythema, particularly with trimethylpsoralen or 5-methoxypsoralen, and is more intense and longer lasting than that produced by sunlight. The efficacy of PUVA is reduced in the presence of intense pigmentation. Therefore, for skin diseases other than vitiligo, higher doses of UVA radiation may be required as treatment proceeds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513870\">",
"    <span class=\"h1\">",
"     TREATMENT PROTOCOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protocols for PUVA treatment were initially developed for the treatment of psoriasis, but may be applied to its use in other conditions. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H770375\">",
"    <span class=\"h2\">",
"     Oral PUVA",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"     Methoxsalen",
"    </a>",
"    capsules are taken orally at doses of 0.4 to 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    actual body weight one to two hours before exposure to UVA radiation (",
"    <a class=\"graphic graphic_table graphicRef83191 \" href=\"mobipreview.htm?18/23/18811\">",
"     table 2",
"    </a>",
"    ). Soft gelatin formulations of methoxsalen (eg, Oxsoralen Ultra���) are absorbed faster and provide higher and more reproducible plasma levels than microcrystalline preparations. (See",
"    <a class=\"local\" href=\"#H3425444\">",
"     'Pharmacokinetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"     Methoxsalen",
"    </a>",
"    ideally should be taken with water on an empty stomach, or at least one hour after eating. However, nausea develops in about 30 percent of patients and is more common with soft gelatin preparations because of rapid absorption and increased blood levels. Nausea can be prevented by taking the drug with a small amount of food with high fat content (eg, cheese) or milk. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513877\">",
"    <span class=\"h3\">",
"     Initial treatment (clearance phase)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of UVA radiation is based upon one of two factors: the patient&rsquo;s skin type (",
"    <a class=\"graphic graphic_table graphicRef83193 graphicRef60541 \" href=\"mobipreview.htm?0/54/877\">",
"     table 3A-B",
"    </a>",
"    ); or the minimal phototoxic dose (MPD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/12,23,24\">",
"     12,23,24",
"    </a>",
"    ]. The latter is more commonly used in a few specialized centers in Europe.",
"   </p>",
"   <p>",
"    The MPD is defined as the minimal dose of UVA that produces a barely perceptible, but well-defined, erythema when template areas of the skin are exposed to increasing doses of UVA after psoralen ingestion. Erythema readings are performed 48 or 72 hours after testing, at which time the psoralen phototoxicity reaction usually reaches its peak. The MPD test should be performed on previously non-exposed skin (eg, buttocks). Treatment is started using 50 to 70 percent of the MPD.",
"   </p>",
"   <p>",
"    Treatments are delivered two or three times per week, at least 48 hours apart. If no erythema is noted, the UVA dose is increased by 0.5 to 1",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in the subsequent treatments until satisfactory control of the disease has been obtained. The dose is then held at that level. If faint erythema is present, the dose of radiation is held constant.",
"   </p>",
"   <p>",
"    If skin tenderness or definite erythema is present, treatment is stopped until erythema and pain have diminished. Treatment is then resumed at a lower dose. If localized erythema develops in previously unexposed parts of the body (eg, the breasts or buttocks), shielding may be employed using clothing or sunscreens that protect against UVA radiation and treatment may be continued.",
"   </p>",
"   <p>",
"    Repeated exposures are usually required to clear PUVA-responsive diseases, with gradual increment in the UVA dose as pigmentation develops. As an example, improvement of moderate plaque psoriasis is generally noted after 8 to 10 treatments. On average, 25 to 30 treatments are needed for complete clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/25-29\">",
"     25-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since arms and legs generally respond to treatment more slowly than the trunk, the extremities may require additional doses of UVA. After the whole body dose, the patient puts on a gown or shorts and t-shirt, and covers his or her head. In patients with skin type I or II, an additional dose of one",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    is delivered to the limbs and increased by 0.5",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    at each subsequent treatment. In patients with skin type &ge;III, additional doses of 2 to 4",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     <strong>",
"     </strong>",
"    </span>",
"    are delivered to the limbs and increased by 0.5 to 1",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    at each treatment.",
"   </p>",
"   <p>",
"    Adherence to the schedule is critical for treatment success. Decreased frequency of PUVA (eg, once weekly) can result in treatment failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513884\">",
"    <span class=\"h3\">",
"     Maintenance treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;After satisfactory clearing of disease, the final dose of UVA is held constant and the frequency of treatments is gradually reduced to as low as once per month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/29\">",
"     29",
"    </a>",
"    ]. Ultimately, PUVA therapy can be discontinued for patients in stable remission to avoid overtreatment and the long-term adverse effects of high cumulative doses of PUVA.",
"   </p>",
"   <p>",
"    Schedules for maintenance treatment and when to discontinue therapy vary between institutions. The optimal interval between treatments and the duration of the maintenance treatment should be determined for the individual patient, based upon the type of disease and the time to relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513891\">",
"    <span class=\"h3\">",
"     Treatment of relapses",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a significant relapse of the disease occurs after treatment discontinuation or during the maintenance phase, it is appropriate to resume a clearance schedule. For minor recurrences occurring during the maintenance phase, the frequency of treatments may be increased until disease control is achieved. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513898\">",
"    <span class=\"h2\">",
"     Alternative psoralen administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;To avoid the gastrointestinal side effects of oral psoralen, protocols have been developed for psoralen to be applied topically (for localized disease) or by bath immersion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1941672\">",
"    <span class=\"h3\">",
"     Topical PUVA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical PUVA may be used as an alternative to oral PUVA in patients with localized diseases, including limited plaque or palmoplantar psoriasis, hand eczema, or localized vitiligo.",
"   </p>",
"   <p>",
"    Topical PUVA consists of direct application to the skin of psoralens in creams, ointments, or lotions followed by exposure to UVA radiation. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"     Methoxsalen",
"    </a>",
"    1% lotion (Oxsolaren&reg;) can be diluted 1:10 with ethanol to yield a 0.1% solution that is applied to affected skin 15 minutes before exposure to UVA radiation.",
"   </p>",
"   <p>",
"    For vitiligo, the initial exposure is 0.5",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Incremental increases of 0.25",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    are given at each treatment thereafter, until a light pink erythema is achieved in the depigmented skin. UVA dose is either held at this level or adjusted with the goal of maintaining a faint erythema in affected skin until repigmentation occurs. Treatment is given two or three times per week.",
"   </p>",
"   <p>",
"    A frequent complication of topical PUVA is an unexpected, usually bullous phototoxic reaction, typically caused by inadvertent exposure to natural sunlight after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1376767\">",
"    <span class=\"h3\">",
"     Bath PUVA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bath PUVA consists of whole body immersion or localized skin soaking (eg, of hands or feet) in a 0.5 to 3",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    solution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"     methoxsalen",
"    </a>",
"    for 15 to 30 minutes. UVA irradiation is performed immediately after, since the photosensitivity decreases rapidly over two hours following immersion.",
"   </p>",
"   <p>",
"    The main advantage of bath PUVA is the absence of systemic adverse effects associated with oral psoralens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/31\">",
"     31",
"    </a>",
"    ]. However, eye protection is still required after bath PUVA since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"     methoxsalen",
"    </a>",
"    is detectable in the blood after topical application [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bath PUVA is not widely available and there is no consensus on the optimal treatment protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/32\">",
"     32",
"    </a>",
"    ]. Bath PUVA is not FDA approved. In addition, the long term adverse effects of bath PUVA, including skin carcinogenesis, are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513912\">",
"    <span class=\"h1\">",
"     SAFETY MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to protect skin that is not involved in the disease process from both topical psoralen and UVA exposure during topical PUVA. When systemic psoralen is taken, the patient must be protected from additional UV exposure after the treatment. The following measures are recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In PUVA units, small UV-blocking goggles are used to protect the eyes. If treatment is not required for facial involvement, the face is protected either by use of a broad spectrum sunscreen with an SPF of 50+ or a cloth barrier. Male genitalia are protected with the use of underwear or an athletic supporter. &nbsp;",
"     </li>",
"     <li>",
"      Patients must protect their eyes after ingesting psoralen (or after bath exposure). Wraparound UV-blocking glasses should be worn when the patient is exposed to sunlight, from the time",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"       methoxsalen",
"      </a>",
"      is ingested until sunset that same day.",
"     </li>",
"     <li>",
"      Sun avoidance is advised to minimize pigmentation from natural sunlight. Excessive pigmentation may ultimately limit the effectiveness of PUVA therapy and require higher doses of UVA. The skin should be protected from natural sunlight through appropriate clothing and avoidance. &nbsp;",
"     </li>",
"     <li>",
"      The amount of UVA emitted by common fluorescent lights is insufficient to activate psoralens. Thus, photoprotection is not required in home or office settings. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1377203\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototoxic drugs (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, or sulfonamides), and topical preparations (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/18/20771?source=see_link\">",
"     anthralin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44724?source=see_link\">",
"     coal tar",
"    </a>",
"    ) may augment the action of PUVA and increase the risk of acute phototoxic erythema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18426?source=see_link&amp;anchor=H22#H22\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Phototoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2099103\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to PUVA treatment are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef83207 \" href=\"mobipreview.htm?23/37/24155\">",
"     table 4",
"    </a>",
"    ). Absolute contraindications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Xeroderma pigmentosa",
"     </li>",
"     <li>",
"      Pregnancy and lactation (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"       methoxsalen",
"      </a>",
"      is a pregnancy category C drug)",
"     </li>",
"     <li>",
"      Lupus erythematosus with a history of photosensitivity or a positive Ro antibody",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PUVA is not contraindicated in patients with cataract or aphakia because most lens implants are UV blocking. The cataracts are protective of the retina. However, patients with cataracts or aphakia should remain particularly vigilant with adequate eye protection measures. (See",
"    <a class=\"local\" href=\"#H31513912\">",
"     'Safety measures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513947\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513954\">",
"    <span class=\"h2\">",
"     Short-term adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short term adverse effects of PUVA therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nausea",
"      </strong>",
"      &ndash; Nausea is the most common adverse reaction induced by oral PUVA. Taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"       methoxsalen",
"      </a>",
"      with a small amount of food with high fat content or milk may prevent or reduce nausea. If nausea persists, the dose of methoxsalen can be decreased by 10 mg. In some patients, antiemetics may be needed. Ginger (ginger ale, ginger snaps) has also been used to reduce the nausea.",
"     </li>",
"     <li>",
"      <strong>",
"       Erythema",
"      </strong>",
"      &ndash; Excessive phototoxicity ranging from intense delayed erythema to blistering occurs in about 10 percent of patients during the clearance phase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/33\">",
"       33",
"      </a>",
"      ]. Treatment is symptomatic and includes cool baths and liberal use of emollients and antipruritics. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30136?source=see_link\">",
"       \"Sunburn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pruritus and skin pain",
"      </strong>",
"      &mdash; Mild pruritus is common and usually associated with skin dryness. Emollients are generally sufficient to relieve this symptom. Intense pruritus (&ldquo;PUVA-itch&rdquo;) is often associated with erythema and is described as a deep, burning itch. PUVA-itch can also occur without erythema. It generally begins on the outer aspect of arms, thighs, buttocks and, in women, on the breasts. Persistent skin pain is an uncommon complication of PUVA therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. Pruritus and pain are thought to be caused by phototoxic damage of the dermal nerve endings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The treatment of pruritus is symptomatic. In severe cases, PUVA should be discontinued until the symptoms resolve (one to three weeks) and resumed using a UVA dose reduced by 10 to 20 percent. There is no definite treatment for PUVA-induced skin pain. A single case report found benefit for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Subacute phototoxicity",
"      </strong>",
"      &ndash; Subacute phototoxicity manifests as a widespread scaly erythema accompanied by intense pruritus and may occur at any point during treatment, even if the UVA dose has been stable for some time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/33\">",
"       33",
"      </a>",
"      ]. An important feature is sparing of areas not exposed to UVA light during treatment (eg, axilla",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inner thigh). Management includes cessation of PUVA therapy, and use of emollients, cool baths, and antipruritic medications until the symptoms subside. PUVA can then be resumed with a UVA dose 30 to 40 percent lower than the last used dose, with gradual increases as tolerated.",
"     </li>",
"     <li>",
"      <strong>",
"       Excessive pigmentation",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Excessive pigmentation is common, especially in patients with skin types &ge;III and may decrease the efficacy of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Other adverse effects",
"      </strong>",
"      &ndash; Other short-term adverse effects include reactivation of herpes simplex, bronchoconstriction, drug fever, heart rate increase, photo-onycholysis and melanonychia, friction blisters, and ankle edema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. Central nervous system disturbances reported with PUVA therapy include headache, dizziness, depression, insomnia, and hyperactivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513961\">",
"    <span class=\"h2\">",
"     Long-term adverse effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513969\">",
"    <span class=\"h3\">",
"     Photoaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photoaging occurs in all patients with Fitzpatrick skin types I to IV after long-term PUVA therapy. These changes are partially reversible upon early discontinuation of therapy. Skin types I and II have more marked changes than types III and IV.",
"   </p>",
"   <p>",
"    The photoaging changes are similar to those produced by natural sunlight and include hyper- or hypopigmentation, telangiectasia, wrinkles, lentigines, and actinic keratosis. Hypertrichosis has been reported to occur in both men and women treated with long term PUVA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/41\">",
"     41",
"    </a>",
"    ]. The lentigines seen with long-term PUVA therapy are composed of melanocytes of larger size and with some cellular atypia. Despite the histologic changes, there is no evidence that PUVA lentigines are precursors of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513976\">",
"    <span class=\"h3\">",
"     Skin cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term studies have demonstrated a dose-related increase in the incidence of nonmelanoma skin cancers among patients exposed to high cumulative doses of oral PUVA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. In a 30-year follow-up study of 1330 patients with psoriasis treated with PUVA, the risk of developing one or more squamous or basal cell carcinomas was greatly increased for those exposed to more than 350 treatments (incidence rate ratio 20.9, 95% CI 14.1-31.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/47\">",
"     47",
"    </a>",
"    ]. In patients previously exposed to PUVA, treatment with cyclosporin further increases the risk of developing skin cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men exposed to PUVA have an increased risk of genital skin cancer. In a cohort of 892 men treated with PUVA, the incidence of invasive scrotal or penile squamous cell carcinoma was 53-fold higher than that expected in the general white population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Controversy surrounds the issue of long-term PUVA and melanoma. In a 25-year follow-up study, melanoma incidence in patients treated with more than 200 PUVA treatments was eight-fold higher than that expected in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/50\">",
"     50",
"    </a>",
"    ]. In contrast, other data primarily from Europe do not show an increased risk of melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/51\">",
"     51",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31513983\">",
"    <span class=\"h3\">",
"     Cataracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term PUVA carries a potential risk for cataract formation. However, a 25-year follow-up study did not show an increased risk of visual impairment or cataract formation in patients treated with PUVA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31514004\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring of patients undergoing PUVA treatment includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/2,53\">",
"     2,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Skin examination",
"      </strong>",
"      &ndash; Complete skin examination for skin cancer, premalignant lesions, and actinic damage is performed before starting treatment and annually thereafter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/53\">",
"       53",
"      </a>",
"      ]. It is also important to educate patients to recognize the signs of skin cancer and perform skin self-examination.",
"     </li>",
"     <li>",
"      <strong>",
"       Eye examination",
"      </strong>",
"      &ndash; Eye examination, including slit-lamp exam of lens and cornea and funduscopic examination of the retina, is performed before starting treatment and annually thereafter. (See",
"      <a class=\"local\" href=\"#H31513912\">",
"       'Safety measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Laboratory tests",
"      </strong>",
"      &ndash; Laboratory tests are not routinely performed before or during PUVA treatment, unless suggested by history (eg, lupus or photosensitivity).",
"     </li>",
"     <li>",
"      <strong>",
"       Outcome evaluation",
"      </strong>",
"      &ndash; The evaluation of disease activity and treatment efficacy is performed by the treating physician at three to four month intervals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ongoing monitoring is indicated in patients who have received prolonged PUVA treatment, since an increased risk of skin cancer may persist after discontinuation of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1377419\">",
"    <span class=\"h1\">",
"     CLINICAL INDICATIONS FOR PUVA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential benefits of PUVA must be weighed against the dose-related risks of long-term therapy in the individual patient. Most common indications for PUVA include moderate to severe psoriasis that is unresponsive to topical therapy and mycosis fungoides. Recognition of the immunosuppressive and antiproliferative effects of PUVA has led to a role for PUVA in the treatment of many other skin diseases, including eczema, vitiligo, and chronic and acute graft-versus-host disease. Additional indications for PUVA therapy are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef83200 \" href=\"mobipreview.htm?6/14/6381\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33160/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of PUVA for the treatment of specific skin conditions is discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment of psoriasis\", section on 'Ultraviolet light'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17017?source=see_link&amp;anchor=H21#H21\">",
"       \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'PUVA'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44457?source=see_link&amp;anchor=H14#H14\">",
"       \"Management of severe refractory atopic dermatitis (eczema)\", section on 'Psoralen plus UVA'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21193?source=see_link&amp;anchor=H13#H13\">",
"       \"Vitiligo\", section on 'Ultraviolet light'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of chronic graft-versus-host disease\", section on 'Psoralen ultraviolet irradiation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31514060\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psoralen plus ultraviolet A (PUVA) photochemotherapy combines the administration of psoralens (",
"      <a class=\"graphic graphic_table graphicRef83021 \" href=\"mobipreview.htm?39/27/40380\">",
"       table 1",
"      </a>",
"      ) with an exposure to ultraviolet A radiation. PUVA is used for the treatment of a variety of skin diseases, including psoriasis, mycosis fungoides, eczema, vitiligo, and graft-versus-host disease. (See",
"      <a class=\"local\" href=\"#H31513778\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31513814\">",
"       'Psoralens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31513828\">",
"       'UVA sources'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms of action of PUVA include: suppression of DNA synthesis and cell proliferation; lymphocyte apoptosis and perturbation in the type and function of antigen presenting cells; changes in cytokine and cytokine receptor expression; melanocyte proliferation and increased melanogenesis. (See",
"      <a class=\"local\" href=\"#H4791974\">",
"       'Mechanisms of action of PUVA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main photosensitivity effects of PUVA include a delayed phototoxic erythema that appears 36 to 48 hours after exposure, and peaks at 48 to 96 hours, and pigmentation. (See",
"      <a class=\"local\" href=\"#H1377222\">",
"       'Photosensitivity effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Protocols for PUVA treatment initially developed for the treatment of psoriasis may be applied to the treatment of other conditions. For oral PUVA, which is the most common type of UVA therapy,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/23/33136?source=see_link\">",
"       methoxsalen",
"      </a>",
"      capsules are taken orally at doses of 0.4 to 0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      one to two hours before exposure to UVA radiation (",
"      <a class=\"graphic graphic_table graphicRef83191 \" href=\"mobipreview.htm?18/23/18811\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H770375\">",
"       'Oral PUVA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The eyes and the skin that is not involved must be protected during PUVA. Additionally, the eyes must be protected from natural sunlight by wearing UV-blocking sunglasses after ingesting psoralens until sunset that same day. (See",
"      <a class=\"local\" href=\"#H31513912\">",
"       'Safety measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Short term adverse effects of PUVA include nausea, erythema, pruritus, and excessive pigmentation. (See",
"      <a class=\"local\" href=\"#H31513954\">",
"       'Short-term adverse effects'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Long-term adverse effects of PUVA include photoaging and increased risk of nonmelanoma skin cancer. Skin examination for skin cancer should be performed annually in patients on PUVA therapy. Ongoing monitoring is indicated in patients who have received prolonged PUVA treatment, since an increased risk of skin cancer may persist after discontinuation of treatment. (See",
"      <a class=\"local\" href=\"#H31513961\">",
"       'Long-term adverse effects'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/1\">",
"      Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974; 291:1207.",
"     </a>",
"    </li>",
"    <li>",
"     Morison WL. Phototherapy and Photochemotherapy of Skin Disease, 3rd ed, Taylor and Francis, New York 2005.",
"    </li>",
"    <li>",
"     Abel EA. Photochemotherapy in Dermatology, Igaku-Shoin, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/4\">",
"      Pathak MA, Fitzpatrick TB. The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. J Photochem Photobiol B 1992; 14:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/5\">",
"      Brickl R, Schmid J, Koss FW. Clinical pharmacology of oral psoralen drugs. Photodermatol 1984; 1:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/6\">",
"      Roelandts R, Van Boven M, Deheyn T, et al. Dietary influences on 8-MOP plasma levels in PUVA patients with psoriasis. Br J Dermatol 1981; 105:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/7\">",
"      Herfst MJ, De Wolff FA. Intraindividual and interindividual variability in 8-methoxypsoralen kinetics and effect in psoriatic patients. Clin Pharmacol Ther 1983; 34:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/8\">",
"      de Wolff FA, Thomas TV. Clinical pharmacokinetics of methoxsalen and other psoralens. Clin Pharmacokinet 1986; 11:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/9\">",
"      Artuc M, Stuettgen G, Schalla W, et al. Reversible binding of 5- and 8-methoxypsoralen to human serum proteins (albumin) and to epidermis in vitro. Br J Dermatol 1979; 101:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/10\">",
"      Wulf HC, Andreasen MP. Distribution of 3H-8-MOP and its metabolites in rat organs after a single oral administration. J Invest Dermatol 1981; 76:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/11\">",
"      Schmid J, Prox A, Reuter A, et al. The metabolism of 8-methoxypsoralen in man. Eur J Drug Metab Pharmacokinet 1980; 5:81.",
"     </a>",
"    </li>",
"    <li>",
"     Honigsmann H, Szemies RM, Knobler R. Photochemotherapy and Photodynamic Therapy. In: Fitzpatrick's Dermatology in General Medicine, 8th Edition, Goldsmith LA, Katz SI, Gilchrest BA, et al.  (Eds), McGraw Hill, New York 2012. Vol 2, p.2851.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/13\">",
"      Viola G, Fortunato E, Cecconet L, et al. Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544. Toxicol Appl Pharmacol 2008; 227:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/14\">",
"      Farr PM, Diffey BL, Higgins EM, Matthews JN. The action spectrum between 320 and 400 nm for clearance of psoriasis by psoralen photochemotherapy. Br J Dermatol 1991; 124:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/15\">",
"      Cripps DJ, Lowe NJ, Lerner AB. Action spectra of topical psoralens: a re-evaluation. Br J Dermatol 1982; 107:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/16\">",
"      Parrish JA, White AD, Kingsbury T, et al. Photochemotherapy of psoriasis using methoxsalen and sunlight. A controlled study. Arch Dermatol 1977; 113:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/17\">",
"      Sethi G, Sodhi A. Role of p38 mitogen-activated protein kinase and caspases in UV-B-induced apoptosis of murine peritoneal macrophages. Photochem Photobiol 2004; 79:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/18\">",
"      Laing TJ, Richardson BC, Toth MB, et al. Ultraviolet light and 8-methoxypsoralen inhibit expression of endothelial adhesion molecules. J Rheumatol 1995; 22:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/19\">",
"      Singh TP, Sch&ouml;n MP, Wallbrecht K, et al. 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010; 184:7257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/20\">",
"      Johnson R, Staiano-Coico L, Austin L, et al. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem Photobiol 1996; 63:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/21\">",
"      Mengeaud V, Ortonne JP. PUVA (5-methoxypsoralen plus UVA) enhances melanogenesis and modulates expression of melanogenic proteins in cultured melanocytes. J Invest Dermatol 1996; 107:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/22\">",
"      Ibbotson SH, Farr PM. The time-course of psoralen ultraviolet A (PUVA) erythema. J Invest Dermatol 1999; 113:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/23\">",
"      Buckley DA, Phillips WG. 8-Methoxypsoralen PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach. Br J Dermatol 1997; 136:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/24\">",
"      Collins P, Wainwright NJ, Amorim I, et al. 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach. Br J Dermatol 1996; 135:248.",
"     </a>",
"    </li>",
"    <li>",
"     Stern RS, Fitzpatrick TB, Honigsmann H, et al. Psoralen photochemotherapy. In: Psoriasis, Roenigk HH, Maibach HI (Eds), Marcel Dekker, New York 1985. p.475.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/26\">",
"      Photochemotherapy for psoriasis. A clinical cooperative study of PUVA-48 and PUVA-64. Arch Dermatol 1979; 115:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/27\">",
"      Henseler T, Wolff K, H&ouml;nigsmann H, Christophers E. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet 1981; 1:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/28\">",
"      Wolff KW, Fitzpatrick TB, Parrish JA, et al. Photochemotherapy for psoriasis with orally administered methoxsalen. Arch Dermatol 1976; 112:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/29\">",
"      Melski JW, Tanenbaum L, Parrish JA, et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 1977; 68:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/30\">",
"      Gange RW, Levins P, Murray J, et al. Prolonged skin photosensitization induced by methoxsalen and subphototoxic UVA irradiation. J Invest Dermatol 1984; 82:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/31\">",
"      Halpern SM, Anstey AV, Dawe RS, et al. Guidelines for topical PUVA: a report of a workshop of the British photodermatology group. Br J Dermatol 2000; 142:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/32\">",
"      Kappes UP, Barta U, Merkel U, et al. High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients. Skin Pharmacol Appl Skin Physiol 2003; 16:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/33\">",
"      Morison WL, Marwaha S, Beck L. PUVA-induced phototoxicity: incidence and causes. J Am Acad Dermatol 1997; 36:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/34\">",
"      Zamiri M, Bilsland D. Treatment of bath PUVA-induced skin pain with gabapentin. Br J Dermatol 2004; 151:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/35\">",
"      Tegner E. Severe skin pain after PUVA treatment. Acta Derm Venereol 1979; 59:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/36\">",
"      Tegner E. Excruciating skin pain after PUVA treatment. Int J Dermatol 1982; 21:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/37\">",
"      Kumakiri M, Hashimoto K, Willis I. Biological changes of human cutaneous nerves caused by ultraviolet irradiation: an ultrastructural study. Br J Dermatol 1978; 99:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/38\">",
"      Prens EP, Smeenk G. Effect of photochemotherapy on the cardiovascular system. Dermatologica 1983; 167:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/39\">",
"      Mackie RM. Onycholysis occurring during PUVA therapy. Clin Exp Dermatol 1979; 4:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/40\">",
"      Ledbetter LS, Hsu S. Melanonychia associated with PUVA therapy. J Am Acad Dermatol 2003; 48:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/41\">",
"      Rampen FH. Hypertrichosis in PUVA-treated patients. Br J Dermatol 1983; 109:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/42\">",
"      Gschnait F, Wolff K, H&ouml;nigsmann H, et al. Long-term photochemotherapy: histopathological and immunofluorescence observations in 243 patients. Br J Dermatol 1980; 103:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/43\">",
"      Rhodes AR, Harrist TJ, Momtaz-T K. The PUVA-induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical, melanocytes. J Am Acad Dermatol 1983; 9:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/44\">",
"      Stern RS. Actinic degeneration and pigmentary change in association with psoralen and UVA treatment: a 20-year prospective study. J Am Acad Dermatol 2003; 48:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/45\">",
"      Lindel&ouml;f B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/46\">",
"      Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998; 134:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/47\">",
"      Stern RS, PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 2012; 66:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/48\">",
"      Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/49\">",
"      Stern RS, Bagheri S, Nichols K, PUVA Follow Up Study. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 2002; 47:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/50\">",
"      Stern RS, Nichols KT, V&auml;kev&auml; LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/51\">",
"      Morison WL, Baughman RD, Day RM, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998; 134:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/52\">",
"      Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol 2007; 57:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33160/abstract/53\">",
"      Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62:114.",
"     </a>",
"    </li>",
"    <li>",
"     Morison WL. PUVA Photochemotherapy. In: Comprehensive Dermatologic Drug Therapy, Second Edition, 2007.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13749 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-89.218.100.194-DA315AB02B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33160=[""].join("\n");
var outline_f32_24_33160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31514060\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31513778\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31513814\">",
"      PSORALENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3425444\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31513821\">",
"      Photochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31513828\">",
"      UVA SOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4791974\">",
"      MECHANISMS OF ACTION OF PUVA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1377222\">",
"      PHOTOSENSITIVITY EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31513870\">",
"      TREATMENT PROTOCOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H770375\">",
"      Oral PUVA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31513877\">",
"      - Initial treatment (clearance phase)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31513884\">",
"      - Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31513891\">",
"      - Treatment of relapses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31513898\">",
"      Alternative psoralen administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1941672\">",
"      - Topical PUVA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1376767\">",
"      - Bath PUVA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31513912\">",
"      SAFETY MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1377203\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2099103\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31513947\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31513954\">",
"      Short-term adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31513961\">",
"      Long-term adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31513969\">",
"      - Photoaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31513976\">",
"      - Skin cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31513983\">",
"      - Cataracts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31514004\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1377419\">",
"      CLINICAL INDICATIONS FOR PUVA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31514060\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13749\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13749|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/4/10309\" title=\"figure 1\">",
"      Psoralens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/13/42198\" title=\"figure 2\">",
"      Psoralen mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/8/15502\" title=\"figure 3\">",
"      Electromagnetic spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13749|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/27/40380\" title=\"table 1\">",
"      Psoralen drugs for PUVA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/23/18811\" title=\"table 2\">",
"      Methoxsalen doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/45/3804\" title=\"table 3A\">",
"      PUVA treatment schedule by skin type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/37/15963\" title=\"table 3B\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/37/24155\" title=\"table 4\">",
"      PUVA contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/14/6381\" title=\"table 5\">",
"      PUVA indications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44457?source=related_link\">",
"      Management of severe refractory atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/27/30136?source=related_link\">",
"      Sunburn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35385?source=related_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17017?source=related_link\">",
"      Treatment of early stage (IA to IIA) mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21193?source=related_link\">",
"      Vitiligo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_24_33161="Bradycardia in children";
var content_f32_24_33161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bradycardia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/24/33161/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33161/contributors\">",
"     Frank Zimmerman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/24/33161/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33161/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/24/33161/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33161/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/24/33161/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradycardia is defined as a heart rate below the lowest normal values set for age. The heart rate is set by the cardiac electric conduction system that also synchronizes the timing of atrial and ventricular contractions. The conduction system includes the sinus node, atrioventricular node (AV), and the His-Purkinje system (His bundle). Bradycardia is caused by intrinsic dysfunction or injury to the heart's conduction system or by extrinsic factors acting on a normal heart and its conduction system.",
"   </p>",
"   <p>",
"    Although bradycardia is less common in children than adults, it can infrequently cause significant morbidity and rarely sudden cardiac death. In particular, the risk of death in untreated children with complete block of the AV node is 5 to 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/1\">",
"     1",
"    </a>",
"    ]. With the advent of pediatric cardiac pacing, these deaths could be prevented. Hence, it is important for the clinician to identify those children with bradycardia who are at risk for morbidity and death and who might benefit from therapeutic intervention.",
"   </p>",
"   <p>",
"    The diagnosis, evaluation, and treatment of bradycardia in children and adolescents will be discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal value for average heart rates varies with age. Younger patients have higher heart rates that decrease to adult values by the late teenage years. Bradycardia can be established by either using 12-lead electrocardiogram (ECG) or by 24-hour ambulatory monitoring.",
"   </p>",
"   <p>",
"    Guidelines for bradycardia based on 12-lead ECG are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Newborn to three years: less than 100 beats per minute.",
"     </li>",
"     <li>",
"      Three to nine years: less than 60 beats per minute.",
"     </li>",
"     <li>",
"      Nine to sixteen years: less than 50 beats per minute.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For 24-hour ambulatory monitoring, the lower limit of normal heart rate for age was calculated as two standard deviations from the mean rate from clinical studies in normal children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Guidelines for bradycardia based on 24-hour ambulatory monitoring are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Newborns to two years: less than 60 beats per minute while asleep and less than 80 beats per minute while awake",
"     </li>",
"     <li>",
"      Two years to six years: less than 60 beats per minute.",
"     </li>",
"     <li>",
"      Six years to 11 years: less than 45 beats per minute.",
"     </li>",
"     <li>",
"      Greater than 11 years (adolescents): less than 40 beats per minute.",
"     </li>",
"     <li>",
"      Greater than 11 years who are well-trained athletes: less than 30 beats per minute.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 24-hour ambulatory guidelines vary from the ECG guidelines as they include the slower heart rates that occur normally at rest and sleep.",
"   </p>",
"   <p>",
"    Normal heart rate ranges by age as demonstrated by a review of observational studies in children from birth to 18 years of age (",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"mobipreview.htm?27/37/28252\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONDUCTION SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of the cardiac conduction system is to initiate and conduct the electrical signal that controls and coordinates atrial and ventricular contraction as reflected in the ECG (",
"    <a class=\"graphic graphic_figure graphicRef76390 \" href=\"mobipreview.htm?30/21/31069\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/8\">",
"     8",
"    </a>",
"    ]. The components of the conduction system include the sinus node, atrioventricular node (AV), and the His-Purkinje system (His bundle).",
"   </p>",
"   <p>",
"    The sinus node is the pacemaker of the heart and is located in the sulcus terminalis at the junction of the superior vena cava and the right atrium. Specialized cells (nodal or dominant cells) within the sinus node depolarize spontaneously, which initiates an electrical impulse that spreads to the AV node and through the atria resulting in bilateral atrial contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/2\">",
"     2",
"    </a>",
"    ]. At the AV node, the impulse is conducted through to the bundle of His. The electrical signal courses through the membranous septum and divides into the right and left bundle branches resulting in nearly simultaneous contraction of the ventricles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6614?source=see_link\">",
"     \"Anatomy and electrophysiology of the sinoatrial node\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the parasympathetic and sympathetic nervous system innervate the cardiac conduction system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased parasympathetic tone via the vagus nerve both decreases sinus node pacing rate and slows the AV node conduction leading to a decrease in heart rate. A very strong vagal response can transiently depress sinus node depolarization (sinus pause) or block transmission through the AV node (complete block).",
"     </li>",
"     <li>",
"      Increased sympathetic tone increases sinus node pacing leading to an increase in heart rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF BRADYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main mechanisms and sites for the development of bradycardia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus bradycardia &mdash; At the sinus node, the depolarization rate is decreased below the lowest normal heart rate values set for age.",
"     </li>",
"     <li>",
"      AV block &mdash; Conduction of the electrical impulse is either delayed or blocked at the AV node or the bundle of His.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of mechanism or site, bradycardia is caused either by intrinsic dysfunction or injury to the heart's conduction system or by extrinsic factors acting on a normal heart and its conduction system (",
"    <a class=\"graphic graphic_table graphicRef65427 \" href=\"mobipreview.htm?36/43/37564\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The two most common causes of bradycardia in children are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Corrective surgery of congenital heart disease &mdash; Injury from either surgery or catheterization is the most common pediatric cause of intrinsic damage to the conduction system. Bradycardia is also seen in some patients with underlying congenital defects prior to surgery.",
"     </li>",
"     <li>",
"      Hypervagotonia and drugs (eg, beta adrenergic blockers). These are the most common pediatric extrinsic causes of bradycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/2\">",
"       2",
"      </a>",
"      ]. Hypervagotonia increases the parasympathetic tone that slows the pacing rate of the sinus node as well as increases the conduction time through the AV node. Drugs can act indirectly through the nervous system or act directly at either the sinus or AV node.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of bradycardia are related directly to the age of the patient, the severity of the bradycardia, and whether there are other cardiac abnormalities. Most patients, regardless of whether underlying heart disease is present, remain asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. In cases of symptomatic bradycardia, clinical manifestations differ by age group:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infants and young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dizziness and syncope are clearly difficult to ascertain in infants and non-verbal young children. Thus, patients often will present with nonspecific symptoms of poor feeding and lethargy. Seizures may occur secondary to unwitnessed syncope. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children and adolescents, bradycardia can present with fatigue, exercise intolerance, dizziness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    syncope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/9,12\">",
"     9,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Severe bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severe bradycardia, cardiac output is insufficient leading to poor systemic perfusion or shock. The most common clinical presentation for severe bradycardia in patients is shock prior to cardio-respiratory arrest. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42901?source=see_link\">",
"     \"Physiology and classification of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe bradycardia can be due to both sinus and AV node dysfunction. This most commonly results from hypoxemia, hypotension, and metabolic acidosis, although intrinsic conduction defects may also be a cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cardiac structural disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rather than findings associated with bradycardia, the signs and symptoms from the underlying cardiac structural abnormality often identify this group of patients with sinus node and AV conduction disturbances. As with children with normal structural hearts, most patients with cardiac disease remain asymptomatic from their bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this group is more susceptible to having symptomatic bradycardia as they have an increased risk for multiple conduction abnormalities and a compromised hemodynamic state. As an example, a decrease in stroke volume due to the underlying cardiac disease coupled with the decrease heart rate may significantly impact upon the patient's cardiac output, thereby leading to cardiac failure.",
"   </p>",
"   <p>",
"    Although uncommon, there is an increased incidence of sudden death in both unoperated and operated patients. As an example, the risk of death in untreated children with complete block of the AV node is reported to be 5 to 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly, there is a 2.5 percent reported incidence of sudden death of patients with a sinoatrial abnormality who had the Mustard operation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Sinus node dysfunction'",
"    </a>",
"    below.) Although no specific etiology was determined, cardiac arrhythmia was considered a high probable cause of death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history should focus upon possible causes of bradycardia and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of medications that either directly or indirectly (via the parasympathetic nervous system) affect the conduction system.",
"     </li>",
"     <li>",
"      Family history of syncope or sudden cardiac death.",
"     </li>",
"     <li>",
"      History of cardiac disease.",
"     </li>",
"     <li>",
"      Past episodes of syncope, dizziness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unexplained seizures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardiac tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     ECG and 24-hour ambulatory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of bradycardia is made with a 12-lead ECG or 24-hour ambulatory monitoring. Conduction abnormalities are divided into sinus node abnormalities (sinus bradycardia) and AV heart block. Heart block is categorized into first degree (slowed conduction without missed beats), second degree (intermittent conduction with missed beats), and third degree or complete AV block (absent conduction).",
"   </p>",
"   <p>",
"    Based upon the ECG findings, the conduction abnormality can be determined. This allows for more focused evaluation and treatment.",
"   </p>",
"   <p>",
"    The conduction defects and their respective ECG findings are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus bradycardia is present when there is a normal sinus appearing P-wave but the rate is below normal for age",
"     </li>",
"     <li>",
"      First-degree AV block occurs when the PR-interval is greater than the upper limits of normal for age (",
"      <a class=\"graphic graphic_waveform graphicRef67882 \" href=\"mobipreview.htm?11/45/11989\">",
"       waveform 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Second-degree AV block is further divided into two categories based on ECG findings, Mobitz type 1 and type 2.",
"     </li>",
"     <li>",
"      In Mobitz type 1 block (also referred to as Wenckebach block), there is progressive prolongation of the PR-interval until a P wave fails to be conducted (",
"      <a class=\"graphic graphic_waveform graphicRef73051 \" href=\"mobipreview.htm?42/35/43573\">",
"       waveform 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In Mobitz type 2 block, the PR interval remains unchanged prior to the P wave that suddenly fails to conduct to the ventricles (",
"      <a class=\"graphic graphic_waveform graphicRef79539 \" href=\"mobipreview.htm?28/37/29270\">",
"       waveform 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Third-degree AV block is also referred to as complete heart block. On ECG, there is complete dissociation of the atrial and ventricular activity. The atrial rate (P wave) is greater than the ventricular rate (QRS complex), which is junctional or ventricular in origin. (",
"      <a class=\"graphic graphic_waveform graphicRef63951 \" href=\"mobipreview.htm?10/23/10609\">",
"       waveform 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise stress testing is not needed in making the diagnosis of bradycardia. However, it is commonly used to determine heart rate response with activity (chronotropic competence). It is helpful in differentiating abnormal cardiac conduction from hypervagotonia as the former fails to respond to exercise while the latter is able to achieve normal peak heart rates. Chronotropic incompetence (the inability to appropriately respond to stress) may be an indication for permanent pacemaker therapy.",
"   </p>",
"   <p>",
"    Invasive electrophysiology testing is rarely required to make the diagnosis. It may be helpful if the mechanism for the arrhythmia remains unclear or if symptoms suggest the presence of a potentially life-threatening arrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ACUTE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of bradycardia is dependent on the clinical circumstances. For asymptomatic patients or those with intermittent but not severe symptoms, the management is discussed under each specific conduction defect.",
"   </p>",
"   <p>",
"    Children who have severe symptomatic bradycardia (poor perfusion or shock) need immediate medical attention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42901?source=see_link\">",
"     \"Physiology and classification of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Heart Association (AHA) guidelines for the acute management of significant bradycardia include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/16\">",
"     16",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_algorithm graphicRef52446 \" href=\"mobipreview.htm?20/4/20545\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess the airway and circulatory system. Provide airway management, oxygenation, and ventilation as needed. Begin chest compressions for heart rate less than 60 beats per minute with poor perfusion, despite adequate ventilation and oxygenation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28948?source=see_link\">",
"       \"Assessment of perfusion in pediatric resuscitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Identify and treat potential reversible causes of refractory bradycardia including hypoxemia, hypothermia, head injury, toxins, and hypervagotonia.",
"     </li>",
"     <li>",
"      Administer epinephrine at a dose of 0.01 mg per kg (concentration 1:10,000; 0.1 ml per kg) intravenously or intraosseously. The dose may be repeated every three to five minutes at the same dose. The maximum single dose is 1 mg. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15738?source=see_link&amp;anchor=H6#H6\">",
"       \"Primary drugs in pediatric resuscitation\", section on 'Epinephrine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Epinephrine can be administered through the endotracheal tube but the dose is higher at 0.1 mg per kg (concentration 1:1000; 0.1 ml per kg).",
"     </li>",
"     <li>",
"      Administer",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      at a dose of 0.02 mg per kg (minimum dose 0.1 mg). The dose may be repeated once. Consider giving atropine before epinephrine, if bradycardia is suspected or known to be due to AV block or hypervagotonia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15738?source=see_link&amp;anchor=H14#H14\">",
"       \"Primary drugs in pediatric resuscitation\", section on 'Atropine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Consider cardiac pacing, particularly if a conduction defect is detected or suspected. Cardiac pacing requires that appropriately trained personal and equipment are available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SINUS BRADYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia is present when there is a normal sinus appearing P-wave on the 12-lead ECG but the rate is below normal for age. Sinus bradycardia may be accompanied by sinus pause or arrest, documented by the sudden absence of an expected sinus P-wave. Sinus pause or absence is due either to failure to generate a sinus node depolarization or failure of a generated sinus node depolarization to exit the sinus node and enter the atria.",
"   </p>",
"   <p>",
"    Sinus bradycardia can be seen in normal asymptomatic children with a benign course and without any apparent underlying pathology. Sinus bradycardia may also be due to an abnormality, impairment or injury of the sinus node commonly referred to as sinus node dysfunction. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Sinus node dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Asymptomatic sinus bradycardia in normal children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia occurs commonly in children, adolescents, and young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The incidence of sinus bradycardia is unknown as most young patients are asymptomatic. In a retrospective review of ECGs of 67,375 patients below 25 years of age, up to 35 percent of asymptomatic individuals had sinus bradycardia at rest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/17\">",
"     17",
"    </a>",
"    ]. There is no prognostic significance of sinus bradycardia in otherwise healthy subjects. The incidence of sinus bradycardia increases in well-conditioned athletes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3878?source=see_link&amp;anchor=H2#H2\">",
"     \"Sinus bradycardia\", section on 'Sinus bradycardia in the normal heart'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Symptomatic sinus bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion will focus on the etiologies of bradycardia that have the potential to cause symptoms in affected patients. (",
"    <a class=\"graphic graphic_table graphicRef65427 \" href=\"mobipreview.htm?36/43/37564\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hypervagotonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypervagotonia includes conditions in which vagal stimulation results in bradycardia. Sinus bradycardia may be accompanied by AV nodal dysfunction that also contributes to symptoms. The combination of the slow heart rate and an associated decline in peripheral vascular resistance are often sufficient to produce presyncope or syncope. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypervagotonia induced bradycardia can be seen in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasopharyngeal or esophageal stimulation with placement of nasogastric or endotracheal tubes, gastro-esophageal reflux, or during suctioning in intubated patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/20-22\">",
"       20-22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Breath-holding spells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. In a study of 58 children with pallid breath-holding spells, ocular compression triggered sinus pause of greater than two seconds in almost 80 percent of patients and greater than four seconds in 55 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastroesophageal reflux (GER) and vomiting &mdash; GER is commonly cited as an etiology for bradycardia in premature neonates. However, a study in preterm infants (average gestational age 29.4 weeks) showed that bradycardia events were preceded by GER in only 2.9 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coughing",
"     </li>",
"     <li>",
"      Increased intracranial pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44633?source=see_link\">",
"       \"Elevated intracranial pressure in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Studies of young adults with obstructive sleep apnea have demonstrated severe bradycardia (heart rates below 30 beats per minute) and asystole of 10 seconds due to enhanced vagal tone. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=see_link\">",
"       \"Cardiovascular effects of obstructive sleep apnea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medications that increase parasympathetic tone resulting in bradycardia include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/37/596?source=see_link\">",
"       edrophonium",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/52/9028?source=see_link\">",
"       physostigmine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/58/16291?source=see_link\">",
"       bethanechol",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/38/44644?source=see_link\">",
"       neostigmine",
"      </a>",
"      , acetylcholine,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/46/41696?source=see_link\">",
"       phenylephrine",
"      </a>",
"      , methoxamine, and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most well trained endurance athletes have resting sinus bradycardia that has traditionally been attributed to increased vagal tone. However, in clinical studies in endurance athletes,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/62/36840?source=see_link\">",
"     propranolol",
"    </a>",
"    failed to alter heart rate. This suggests that in these patients that the intrinsic physiology of the sinoatrial node may be altered rather than be attributable to changes in vagal tone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23192?source=see_link&amp;anchor=H4#H4\">",
"     \"Arrhythmia in athletes\", section on 'Sinus and AV node dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Sinus node dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In sinus node dysfunction, there is inappropriate sinus bradycardia or chronotropic incompetence (failure to appropriately elevate the heart rate in response to physiological stress). In addition to sinus bradycardia, other findings associated with nodal dysfunction include severe sinus pauses, the",
"    <span class=\"nowrap\">",
"     tachycardia/bradycardia",
"    </span>",
"    syndrome, sinus node reentry tachycardia and sinoatrial exit block. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22008?source=see_link\">",
"     \"Manifestations and causes of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Causes are either due to congenital or acquired myocardial disease. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Familial &mdash; Familial bradycardia is a rare disorder. There are multiple case reports describing families with an autosomal dominant pattern of inheritance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. In these reports, syncope has been associated with the bradycardia. A severe form of bradycardia called atrial standstill, in which there is absence of atrial activity, has been reported to also have a familial pattern of inheritance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/27\">",
"       27",
"      </a>",
"      ].Mutations in the cardiac sodium channel gene SCN5A may be responsible for at least some familial cases. In a study of 10 children from seven families with familial sick sinus syndrome, genomic DNA encoding the alpha subunit of the cardiac sodium channel was screened for mutations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/28\">",
"       28",
"      </a>",
"      ]. In five children from three families (but in none of over 75 control subjects), compound heterozygous nucleotide changes were identified.",
"      <br/>",
"      <br/>",
"      Two of these mutations in SCN5A were previously reported to cause other forms of congenital cardiac arrhythmia (Brugada syndrome and long QT syndrome). Other mutations at this locus have been associated with familial AV block and with familial dilated cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28681?source=see_link\">",
"       \"Genetics of congenital and acquired long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=see_link\">",
"       \"Etiology of atrioventricular block\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39576?source=see_link\">",
"       \"Genetics of dilated cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital heart disease &mdash; Sinus node dysfunction has been seen in a variety of congenital heart disease, with atrial septal defect (ASD) being the most common lesion. Concomitant AV nodal dysfunction is also observed in patients with ASD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/9,29,30\">",
"       9,29,30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other congenital heart diseases associated with sinus node dysfunction include atrioventricular canal, pulmonary stenosis, ventricular septal defect, transposition of the great arteries, and Wolff Parkinson White syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/9,31,32\">",
"       9,31,32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Sinus node dysfunction and associated atrial arrhythmias occur after surgical repair of congenital lesions. This is found most commonly in repairs to the atrial wall that injure the sinus node, sinus node artery or innervation of the sinus node [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/9,14,30,33,34\">",
"       9,14,30,33,34",
"      </a>",
"      ]. The incidence is highest in patients with transposition of the great arteries with Mustard or Senning procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/14,33\">",
"       14,33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      This was best shown in a retrospective review of 372 patients with complete transposition of the great arteries who survived the Mustard operation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/14\">",
"       14",
"      </a>",
"      ]. At one year, 76 percent of corrected patients had normal sinus rhythm that decreased to 57 percent by eight years. Nine of the patients died suddenly. Though no etiology was determined, cardiac arrhythmia was considered a high probable cause of death.",
"     </li>",
"     <li>",
"      Myocardial disease &mdash; Acquired or familial myocardial diseases such as cardiomyopathy, inflammatory (myocarditis and pericarditis) or ischemic diseases can cause sinus node dysfunction. Though ischemic disease is uncommon in children, cardiac conduction abnormalities have been found in patients with Kawasaki's disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22008?source=see_link\">",
"       \"Manifestations and causes of the sick sinus syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=see_link\">",
"       \"Cardiovascular sequelae of Kawasaki disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Myocardial ischemia due to hypoxemia or hypotension is a cause of sinus nodal dysfunction that requires immediate attention. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypothermia",
"     </li>",
"     <li>",
"      Medications &mdash; Various medications, particularly antiarrhythmia agents, are associated with sinus node dysfunction. Medication-induced sinus node dysfunction is most common in children who have had corrective cardiac surgery. These drugs should be used with caution and patients need to be carefully monitored to see whether they require pacemaker therapy. Cardiac drugs include digitalis, beta blockers (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/62/36840?source=see_link\">",
"       propranolol",
"      </a>",
"      ), calcium channel blockers (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/3/33849?source=see_link\">",
"       verapamil",
"      </a>",
"      ), and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/41/9882?source=see_link\">",
"       amiodarone",
"      </a>",
"      . Non-cardiac drugs include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/38/1639?source=see_link\">",
"       lithium",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"       clonidine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22008?source=see_link&amp;anchor=H4#H4\">",
"       \"Manifestations and causes of the sick sinus syndrome\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Miscellaneous causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus node dysfunction has been observed in a variety of diseases. These include",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long QT syndrome &mdash; The sinus node dysfunction may be due to the cardiac sodium channel gene defect, which underlies some forms of the long QT syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features of congenital long QT syndrome\", section on 'Bradycardia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sudden infant death syndrome (SIDS) &mdash; Although there is speculation that cardiac conduction abnormalities play a causative role in SIDS, the clinical correlation between SIDS and sinus bradycardia is weak [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/35\">",
"       35",
"      </a>",
"      ]. However, there are autopsy studies that have noted the sinus node arterial diameter to be reduced in some SIDS victims [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37194?source=see_link\">",
"       \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Right atrial tumors have been associated with sinus nodal dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obstructive jaundice has also been associated with sinus nodal dysfunction but the mechanism is unknown [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anorexia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/40\">",
"       40",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Neonatal lupus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Apnea and bradycardia of prematurity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for sinus bradycardia is usually based on the presence or absence of symptoms. Acute management of severe bradycardia is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Acute management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Chronic medical therapy for symptomatic sinus bradycardia is usually not effective due to variable response over time. There are also unacceptable side effects of the medications.",
"   </p>",
"   <p>",
"    Pacemaker implantation is recommended for chronic therapy for symptomatic sinus bradycardia. The recommendations contained in the Report of the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society 2008 Task Force on Practice Guidelines",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    are as follows for sinus bradycardia in children, adolescents, and patients (",
"    <a class=\"graphic graphic_table graphicRef54980 \" href=\"mobipreview.htm?17/27/17853\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These guidelines are based in part on the degree of evidence and general consensus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class I &mdash; Class I conditions are those for which there is evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      general agreement that a permanent pacemaker should be implanted. This class includes patients with sinus node dysfunction with correlation of symptoms during bradycardia defined by patient age.",
"     </li>",
"     <li>",
"      Class II &mdash; Class II conditions are those for which permanent pacemakers are frequently used, but there is divergence of opinion with respect to the necessity of their insertion. This includes: patients with congenital heart disease and sinus bradycardia for the prevention of recurrent episodes of intra-atrial reentry tachycardia; patients with congenital heart disease and impaired hemodynamics due to sinus bradycardia; and asymptomatic sinus bradycardia in the adolescent with congenital heart disease with resting heart rate of less than 40 beats per minute or pauses in ventricular rate greater than 3 seconds.",
"      <br/>",
"      <br/>",
"      Class IIA conditions includes patients with sinus bradycardia with recurrent intra-atrial reentrant tachycardia, congenital heart disease and impaired hemodynamics due to sinus bradycardia, and asymptomatic sinus bradycardia with congenital heart disease with resting heart rate of less than 40 beats per minute or pauses in ventricular rate greater than 3 seconds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In asymptomatic young patients without structural heart disease, there is no accepted lower limit of heart rate that would warrant intervention. However, in children with congenital heart disease especially after surgical repair, sinus node dysfunction is often treated, even if asymptomatic. The rationale for treatment is based on the concern that bradycardia has been associated with heart failure, hemodynamic compromise, and rarely sudden cardiac death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     AV HEART BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an atrial impulse to the ventricles due to an anatomical or functional impairment in the conduction system. The conduction can be delayed, intermittent, or absent. Heart block is categorized into first degree (slowed conduction without missed beats), second degree (intermittent conduction with missed beats), and third degree or complete AV block (absent conduction).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     First-degree AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although first-degree AV block does",
"    <strong>",
"     not",
"    </strong>",
"    cause bradycardia, it is worthwhile to review the clinical features of this finding since it is common and most be distinguished from other forms of AV nodal dysfunction. First-degree AV block occurs when the PR-interval is greater than the upper limits of normal for age (",
"    <a class=\"graphic graphic_waveform graphicRef67882 \" href=\"mobipreview.htm?11/45/11989\">",
"     waveform 1",
"    </a>",
"    ). The PR interval is the conduction time from the sinus node through the atrium, AV node and the His-Purkinje system to the start of ventricular depolarization. This interval is both age and rate dependent. In general, the normal PR-intervals are: 70 to 170 msec in newborns, and 80 to 220 msec in young children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    First-degree AV block is a common ECG finding, which reportedly occurs in up to 6 percent of normal neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/45\">",
"     45",
"    </a>",
"    ]. Although the conduction time from the sinus node to the ventricles is increased, bradycardia does not occur since AV conduction remains intact. There is an association with sinus node dysfunction or AV node disease in affected patients.",
"   </p>",
"   <p>",
"    Diseases associated with first-degree AV block include rheumatic fever, Chagas disease, rubella, mumps, hypothermia, cardiomyopathy, metabolic disorders (hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoglycemia, and hypomagnesemia), and hypervagotonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with first-degree AV block are usually asymptomatic. Routine monitoring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment may be indicated if there is evidence of coexisting sinus or AV node dysfunction. With extreme PR interval prolongation, patients develop pacemaker syndrome (dizziness, fatigue or chest discomfort) due to simultaneous contraction of the atria and ventricles. Pacemaker therapy may be indicated for these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further discussion including the clinical manifestations and implications of first-degree AV block at different sites in the conduction system is found elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41574?source=see_link\">",
"     \"First degree atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Second-degree AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;In second-degree AV block, the organized atrial impulse fails to be conducted to the ventricle in a 1:1 ratio. Wenckebach first described second-degree AV block and Mobitz later divided it into two categories based on ECG findings. These two types have different sites of involvement and prognoses especially in progression to complete heart block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Mobitz type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mobitz type 1 block is also referred to as Wenckebach block. On ECG, there is progressive prolongation of the PR-interval until a P wave fails to be conducted (",
"    <a class=\"graphic graphic_waveform graphicRef73051 \" href=\"mobipreview.htm?42/35/43573\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Mobitz type 1 block is seen in normal children and young adults especially at times of high parasympathetic tone (eg, sleep or in well-trained athletes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In one study, Mobitz type 1 block was seen in 6 percent of medical students during sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with Mobitz type 1 block are generally asymptomatic. The block is located at the level of the AV node and is usually not associated with other significant conduction system disease. In addition, it does not progress to complete block.",
"   </p>",
"   <p>",
"    It may also be seen in patients with intrinsic AV nodal disease, myocarditis including Chagas disease, myocardial infarction or following cardiac surgery. These conditions may be associated with other conduction abnormalities.",
"   </p>",
"   <p>",
"    Treatment is usually not indicated unless there is evidence for other more significant conduction system disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Acute management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Mobitz type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mobitz type 2 block is diagnosed on ECG when the PR interval remains unchanged prior to the P wave that suddenly fails to conduct to the ventricles (",
"    <a class=\"graphic graphic_waveform graphicRef79539 \" href=\"mobipreview.htm?28/37/29270\">",
"     waveform 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mobitz type 2 block occurs less frequently than type 1, but its presence has more significant clinical implications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/19\">",
"     19",
"    </a>",
"    ]. It is associated with various forms of congenital heart disease and is seen after cardiac surgery. Type 2 block occurs at or below the level of the AV node, indicating disease within the His bundle and bundle branches. It has a less predictable course and frequently progresses to complete heart block. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Third-degree AV block'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Acute management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Advanced second-degree AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced second-degree AV block is diagnosed on ECG when there are two consecutive P waves present that should but fail to conduct to the ventricle. This indicates significant conduction disease below the level of the AV node.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Third-degree AV block",
"    </span>",
"    &nbsp;&mdash;&nbsp;In third-degree AV block, also referred to as complete heart block, there is complete failure of the atrial impulse to be conducted to the ventricles (",
"    <a class=\"graphic graphic_waveform graphicRef65545 \" href=\"mobipreview.htm?12/50/13095\">",
"     waveform 5",
"    </a>",
"    ). The atrial and ventricular activity are independent of one another. The escape rhythm that is generated is dictated by the location of the block. It is usually slower than the lower limits of normal for age, resulting in bradycardia.",
"   </p>",
"   <p>",
"    The etiology of complete block can be divided into congenital and acquired causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Congenital complete heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal lupus, due to maternal antibodies (RO-SSA and LA-SSB) that cross the placenta, is responsible for 60 to 90 percent of congenital complete heart block cases. Other causes include myocarditis and various structural cardiac defects, particularly congenitally corrected transposition of the great arteries, atrioventricular discordance, or polysplenia with atrioventricular canal defect. The clinical manifestations, presentation, and treatment of congenital complete heart block are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10376?source=see_link\">",
"     \"Congenital third degree (complete) atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Familial AV conduction block, characterized by a progression in the degree of block in association with a variable apparent site of block, may be transmitted as an autosomal dominant trait. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology of atrioventricular block\", section on 'Familial disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Acquired complete heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of acquired heart block include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myocarditis",
"     </li>",
"     <li>",
"      Acute rheumatic disease",
"     </li>",
"     <li>",
"      Myocardial infarction",
"     </li>",
"     <li>",
"      Trauma",
"     </li>",
"     <li>",
"      Injury from surgery or catheterization",
"     </li>",
"     <li>",
"      Cardiomyopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with complete heart block and structural heart disease are at increased risk for heart failure as their ability to maintain an adequate cardiac output may be compromised from the low heart rate and a possible reduction in stroke volume. These patients are also at increased risk for sudden cardiac death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Pacemaker indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for second- and third-degree complete heart block is usually based on the presence or absence of symptoms. Acute management of severe bradycardia is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Acute management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    2008 recommendations for a permanent pacemaker in children and adolescents are based in part on the degree of evidence and general consensus. (",
"    <a class=\"graphic graphic_table graphicRef54980 \" href=\"mobipreview.htm?17/27/17853\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33161/abstract/43\">",
"     43",
"    </a>",
"    ]. These recommendations are divided into the different classes based upon the strength of evidence and opinion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class I &mdash; Class I conditions for which there is evidence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      general agreement that a permanent pacemaker should be implanted in children and adolescents with heart block include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Third and advanced second-degree AV heart block that is associated with symptomatic bradycardia, ventricular dysfunction, or low cardiac output.",
"     </li>",
"     <li>",
"      Children who have third or advanced second-degree AV heart block after cardiac surgery that is not expected to resolve or that persists seven days after surgery.",
"     </li>",
"     <li>",
"      Infants with congenital third-degree heart block who have a wide QRS escape rhythm, complex ventricular ectopy, ventricular dysfunction, or a heart rate less than 55 beats per minute.",
"     </li>",
"     <li>",
"      Infants with congenital third-degree heart block and congenital heart disease who have a heart rate less than 70 beats per minute.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class II &mdash; Class II conditions are those for which permanent pacemakers are frequently used, but there is divergence of opinion with respect to the necessity of their insertion. This class is divided into Class IIa, in which the evidence or opinion favors the usefulness of permanent pacing, and Class IIb, in which the evidence or opinion is less well established for permanent pacing.",
"      <br/>",
"      <br/>",
"      Class IIa indications for pacemaker therapy for children and adolescents with heart block includes asymptomatic patients with third-degree heart block older than one year of age with congenital heart block with a heart rate less than 50 beats per minute, abrupt pauses in ventricular rate (two or three times the basic cycle length), or are symptomatic upon exertion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with complete heart block also require a serial annual echocardiograms to evaluate and monitor left ventricular size and function over time as complete heart block has been associated with the later development of cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/46/8931?source=see_link\">",
"       \"Patient information: Bradycardia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/26/44449?source=see_link\">",
"       \"Patient information: Heart block in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/57/20369?source=see_link\">",
"       \"Patient information: Heart block in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is the summary of the above discussion on bradycardia in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bradycardia is defined as a heart rate below the lowest normal values set for age. Two main physiological mechanisms are sinus bradycardia and AV block. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis of bradycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children with bradycardia are asymptomatic including those with structural cardiac disease. Symptoms vary with age. Infants and non-verbal children present with non-specific symptoms including lethargy, poor feeding,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      seizures. Older children and adolescents will complain of dizziness, fatigue, exercise intolerance",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      syncope. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe bradycardia have insufficient cardiac output and poor peripheral perfusion. They require immediate medical attention. Acute management includes assessing and restoring the cardio-respiratory state and identifying reversible causes of bradycardia. Medical management includes administration of epinephrine,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiac pacing. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic sinus bradycardia is a common finding in normal children. There is no prognostic significance to sinus bradycardia in otherwise healthy subjects. Increased vagal tone can cause sinus bradycardia that may be symptomatic. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Asymptomatic sinus bradycardia in normal children'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Hypervagotonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sinus nodal dysfunction, defined as inappropriate sinus bradycardia or inability to appropriately elevate the heart rate in response to physiological stress, can be caused by congenital, familial, or cardiac disease. It can also be acquired from direct injury (surgery), inflammation (myocarditis), or medications especially antiarrhythmic agents. Treatment is based on the severity of symptoms. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Sinus node dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AV heart block is the delay or interruption in the transmission of an atrial impulse to the ventricles. It is categorized into first-degree (slowed conduction without missed beats), second-degree (intermittent conduction with missed beats), and third-degree or complete block (absent conduction). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'AV Heart block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First-degree heart block is found in normal asymptomatic children and does not cause bradycardia. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'First-degree AV block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Second-degree heart block is divided by ECG findings into Mobitz Type 1 and II. Children with Mobitz type II heart block are more likely to have underlying cardiac disease and are at increased risk to progress to complete heart block. In some of these children, pacemaker therapy should be considered. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Second-degree AV block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Third-degree heart block or complete block can be congenital or acquired. In the neonate, the most common cause is due to neonatal lupus. Children with structural heart disease and complete block are at increased risk for developing heart failure and are at increased risk for sudden cardiac disease. In these patients, pacemaker therapy is recommended. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Third-degree AV block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart",
"      <span class=\"nowrap\">",
"       Association/Heart",
"      </span>",
"      Rhythm Society published guidelines in 2008 for the use of permanent pacing in children, adolescents, and patients including those with sinus bradycardia and heart block (",
"      <a class=\"graphic graphic_table graphicRef54980 \" href=\"mobipreview.htm?17/27/17853\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Michaelson M, Engle MA. Congenital complete heart block: An international study of the natural history. In: Cardiovascular Clinics, Brest AN, Engle MA (Eds), FA Davis, Philadelphia 1972. p.85.",
"    </li>",
"    <li>",
"     Kugler JD. Sinus node dysfunction. In: Pediatric Arrhythmias: Electrophysiology and Pacing, Gillette PC, Garson AG Jr (Eds), WB Saunders, Philadelphia 1990. p.250.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/3\">",
"      Richards JM, Alexander JR, Shinebourne EA, et al. Sequential 22-hour profiles of breathing patterns and heart rate in 110 full-term infants during their first 6 months of life. Pediatrics 1984; 74:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/4\">",
"      Southall DP, Johnston F, Shinebourne EA, Johnston PG. 24-hour electrocardiographic study of heart rate and rhythm patterns in population of healthy children. Br Heart J 1981; 45:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/5\">",
"      Southall DP, Keeton BR, Leanage R, et al. Cardiac rhythm and conduction before and after Mustard's operation for complete transposition of the great arteries. Br Heart J 1980; 43:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/6\">",
"      Montague TJ, Taylor PG, Stockton R, et al. The spectrum of cardiac rate and rhythm in normal newborns. Pediatr Cardiol 1982; 2:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/7\">",
"      Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet 2011; 377:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/8\">",
"      Mangrum JM, DiMarco JP. The evaluation and management of bradycardia. N Engl J Med 2000; 342:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/9\">",
"      Yabek SM, Jarmakani JM. Sinus node dysfunction in children, adolescents, and young adults. Pediatrics 1978; 61:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/10\">",
"      Rein AJ, Simcha A, Ludomirsky A, et al. Symptomatic sinus bradycardia in infants with structurally normal hearts. J Pediatr 1985; 107:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/11\">",
"      Bricker JT, Garson A Jr, Gillette PC. A family history of seizures associated with sudden cardiac deaths. Am J Dis Child 1984; 138:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/12\">",
"      Beder SD, Cohen MH, Riemenschneider TA. Occult arrhythmias as the etiology of unexplained syncope in children with structurally normal hearts. Am Heart J 1985; 109:309.",
"     </a>",
"    </li>",
"    <li>",
"     Pediatric Advanced Life Support Provider Manual. Ralston, M, et al (Eds), American Heart Association, Subcommittee on Pediatric Resuscitation, Dallas, 2006. p.116.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/14\">",
"      Flinn CJ, Wolff GS, Dick M 2nd, et al. Cardiac rhythm after the Mustard operation for complete transposition of the great arteries. N Engl J Med 1984; 310:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/15\">",
"      Guidelines for Clinical Intracardiac Electrophysiological and Catheter Ablation Procedures. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures). Developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 1995; 92:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/16\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/17\">",
"      HISS RG, LAMB LE, ALLEN MF. Electrocardiographic findings in 67,375 asymptomatic subjects. X. Normal values. Am J Cardiol 1960; 6:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/18\">",
"      Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977; 39:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/19\">",
"      Dickinson DF, Scott O. Ambulatory electrocardiographic monitoring in 100 healthy teenage boys. Br Heart J 1984; 51:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/20\">",
"      Guilleminault C, Coons S. Apnea and bradycardia during feeding in infants weighing greater than 2000 gm. J Pediatr 1984; 104:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/21\">",
"      Font&aacute;n JP, Heldt GP, Heyman MB, et al. Esophageal spasm associated with apnea and bradycardia in an infant. Pediatrics 1984; 73:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/22\">",
"      Kenigsberg K, Griswold PG, Buckley BJ, et al. Cardiac effects of esophageal stimulation: possible relationship between gastroesophageal reflux (GER) and sudden infant death syndrome (SIDS). J Pediatr Surg 1983; 18:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/23\">",
"      Lombroso CT, Lerman P. Breathholding spells (cyanotic and pallid infantile syncope). Pediatrics 1967; 39:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/24\">",
"      Stephenson JB. Reflex anoxic seizures ('white breath-holding'): nonepileptic vagal attacks. Arch Dis Child 1978; 53:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/25\">",
"      Di Fiore J, Arko M, Herynk B, et al. Characterization of cardiorespiratory events following gastroesophageal reflux in preterm infants. J Perinatol 2010; 30:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/26\">",
"      Swiryn S, McDonough T, Hueter DC. Sinus node function and dysfunction. Med Clin North Am 1984; 68:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/27\">",
"      Ward DE, Ho SY, Shinebourne EA. Familial atrial standstill and inexcitability in childhood. Am J Cardiol 1984; 53:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/28\">",
"      Benson DW, Wang DW, Dyment M, et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest 2003; 112:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/29\">",
"      Ruschhaupt DG, Khoury L, Thilenius OG, et al. Electrophysiologic abnormalities of children with ostium secundum atrial septal defect. Am J Cardiol 1984; 53:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/30\">",
"      Bolens M, Friedli B. Sinus node function and conduction system before and after surgery for secundum atrial septal defect: an electrophysiologic study. Am J Cardiol 1984; 53:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/31\">",
"      Fournier A, Young ML, Garcia OL, et al. Electrophysiologic cardiac function before and after surgery in children with atrioventricular canal. Am J Cardiol 1986; 57:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/32\">",
"      Rakovec P, Rode P, Jakopin J, Horvat M. Latent sinoatrial conduction disturbances in symptomatic patients with Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 1983; 6:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/33\">",
"      Duster MC, Bink-Boelkens MT, Wampler D, et al. Long-term follow-up of dysrhythmias following the Mustard procedure. Am Heart J 1985; 109:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/34\">",
"      Kavey RE, Gaum WE, Byrum CJ, et al. Loss of sinus rhythm after total cavopulmonary connection. Circulation 1995; 92:II304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/35\">",
"      Colan SD, Liberthson RR, Cahen L, et al. Incidence and significance of primary abnormalities of cardiac rhythm in infants at high risk for sudden infant death syndrome. Pediatr Cardiol 1984; 5:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/36\">",
"      Anderson KR, Hill RW. Occlusive lesions of cardiac conducting tissue arteries in sudden infant death syndrome. Pediatrics 1982; 69:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/37\">",
"      Kozakewich HP, McManus BM, Vawter GF. The sinus node in sudden infant death syndrome. Circulation 1982; 65:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/38\">",
"      Bini RM, Westaby S, Bargeron LM Jr, et al. Investigation and management of primary cardiac tumors in infants and children. J Am Coll Cardiol 1983; 2:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/39\">",
"      Bashour TT, Antonini C Sr, Fisher J. Severe sinus node dysfunction in obstructive jaundice. Ann Intern Med 1985; 103:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/40\">",
"      Miller KK, Grinspoon SK, Ciampa J, et al. Medical findings in outpatients with anorexia nervosa. Arch Intern Med 2005; 165:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/41\">",
"      Brucato A, Previtali E, Ramoni V, Ghidoni S. Arrhythmias presenting in neonatal lupus. Scand J Immunol 2010; 72:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/42\">",
"      Baird TM. Clinical correlates, natural history and outcome of neonatal apnoea. Semin Neonatol 2004; 9:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33161/abstract/43\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51:e1.",
"     </a>",
"    </li>",
"    <li>",
"     Garson A Jr. Arrhythmias. In: The Electrocardiogram in Infants and Children: A Systematic Approach, Lea &amp; Febiger, Philadelphia 1983. p.195.",
"    </li>",
"    <li>",
"     Ferrer PL. Arrhythmias in the neonate. In: Arrhythmias n the neonate, infant, and child, Roberts NK, Gleband H (Eds), Appleton-Century-Crofts, New York 1977. p.265.",
"    </li>",
"    <li>",
"     Ross BA, Trippel DL. Atrioventricular block. In: Garson A, Bricker JT, Fisher DJ, Neish SR, The science and practice of pediatric cardiology (Ed), Willilmans &amp; Wilkins, Philadelphia 1998. p.2048.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5759 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33161=[""].join("\n");
var outline_f32_24_33161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONDUCTION SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS OF BRADYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infants and young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Severe bradycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cardiac structural disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardiac tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - ECG and 24-hour ambulatory monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ACUTE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SINUS BRADYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Asymptomatic sinus bradycardia in normal children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Symptomatic sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hypervagotonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Sinus node dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      AV HEART BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      First-degree AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Second-degree AV block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Mobitz type 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Mobitz type 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Advanced second-degree AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Third-degree AV block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Congenital complete heart block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Acquired complete heart block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Pacemaker indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5759\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5759|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?20/4/20545\" title=\"algorithm 1\">",
"      Pediatric bradycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5759|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/21/31069\" title=\"figure 1\">",
"      Generation of ECG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5759|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/37/28252\" title=\"table 1\">",
"      Normal respiratory rate and heart rate in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/43/37564\" title=\"table 2\">",
"      causes bradycardia children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/27/17853\" title=\"table 3\">",
"      ACC AHA HRS congenital HD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5759|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?11/45/11989\" title=\"waveform 1\">",
"      ECG first degree AV block I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/35/43573\" title=\"waveform 2\">",
"      ECG Mobitz type I AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?28/37/29270\" title=\"waveform 3\">",
"      ECG Mobitz type II AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?10/23/10609\" title=\"waveform 4\">",
"      ECG third degree AV block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?12/50/13095\" title=\"waveform 5\">",
"      Third degree or complete AV block with narrow QRS escape",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6614?source=related_link\">",
"      Anatomy and electrophysiology of the sinoatrial node",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28948?source=related_link\">",
"      Assessment of perfusion in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10376?source=related_link\">",
"      Congenital third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41574?source=related_link\">",
"      First degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/46/8931?source=related_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/26/44449?source=related_link\">",
"      Patient information: Heart block in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/57/20369?source=related_link\">",
"      Patient information: Heart block in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42901?source=related_link\">",
"      Physiology and classification of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15738?source=related_link\">",
"      Primary drugs in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3878?source=related_link\">",
"      Sinus bradycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_24_33162="Treatment of malignant germ cell tumors of the ovary";
var content_f32_24_33162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of malignant germ cell tumors of the ovary",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/24/33162/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33162/contributors\">",
"     Eva Chalas, MD, FACOG, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33162/contributors\">",
"     Fidel A Valea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33162/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/24/33162/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33162/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33162/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/24/33162/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33162/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/24/33162/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/24/33162/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant germ cell cancers of the ovary include dysgerminomas, immature teratomas, embryonal cell carcinoma, endodermal sinus (also called yolk sac) tumors, primary ovarian (nongestational) choriocarcinomas, polyembryoma, and mixed germ cell tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/1\">",
"     1",
"    </a>",
"    ]. In general, the treatment principles for all types of malignant ovarian germ cell tumor (OGCT) are similar to those that guide the management of the more common epithelial ovarian cancer (EOC), with some exceptions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery is required for diagnosis, staging, and treatment. As with EOC, the abdomen should be thoroughly explored, with complete surgical staging and optimal cytoreduction when safe and feasible. In contrast to EOC, most OGCTs are stage I (",
"      <a class=\"graphic graphic_table graphicRef51205 \" href=\"mobipreview.htm?14/43/15038\">",
"       table 1",
"      </a>",
"      ) at initial presentation, and most patients can be safely treated with fertility-preserving surgery rather than total abdominal hysterectomy and bilateral salpingo-oophorectomy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=see_link\">",
"       \"Epithelial ovarian cancer: Initial surgical management\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Malignant OGCTs are highly sensitive to platinum-based chemotherapy. This fact, coupled with the poor outcomes from surgery alone (even for stage I disease), has led to routine administration of adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy to most adult patients except those with stage I dysgerminoma and well-differentiated stage I immature teratoma. In contrast to advanced EOC, women with advanced stage OGCTs can often be cured. &nbsp;",
"     </li>",
"     <li>",
"      Like EOCs, which produce the tumor marker CA 125, many OGCTs produce tumor products (alpha fetoprotein [AFP], human chorionic gonadotropin [hCG], lactate dehydrogenase [LDH]) that can be measured in the serum. The presence of these markers provides a highly sensitive and specific indicator of the presence of certain histologic components (",
"      <a class=\"graphic graphic_table graphicRef55817 \" href=\"mobipreview.htm?24/4/24653\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assay of these serum tumor markers prior to definitive treatment can provide a diagnostic clue to the presence of an OGCT in a (particularly young) woman or girl with an adnexal mass. Furthermore, serial assay of these tumor markers is useful for monitoring the response to chemotherapy and for subsequent posttreatment follow-up. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of malignant OGCTs will be reviewed here. Pathology and clinical manifestations of these neoplasms, as well as treatment of benign OGCTs, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=see_link\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGING AND PATTERN OF SPREAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging system used for OGCTs is identical to that used for EOC (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"mobipreview.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ). Malignant OGCTs spread via the lymphatics, bloodstream, or by peritoneal surface dissemination. In contrast to EOC, nodal involvement is more common with malignant OGCTs, and they have a somewhat greater predilection for hematogenous metastases to the liver and lung.",
"   </p>",
"   <p>",
"    In a large retrospective study, the overall prevalence of lymph node metastasis in OGCTs varied by histology, dysgerminoma (28 percent), mixed germ cell tumors (including pure non-dysgerminoma) (16 percent), and malignant teratoma (8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/2\">",
"     2",
"    </a>",
"    ]. Lymph node involvement was an independent predictor of poor survival with a hazards ratio of 2.9 (95% CI, 1.4&ndash;5.7).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRIMARY SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management of OGCTs is both diagnostic and therapeutic. In general, the scope of the operative procedure depends upon the surgical findings and the patient's desire to maintain fertility or avoid exogenous estrogen supplementation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A generous midline vertical incision is recommended to allow for adequate exposure and a thorough evaluation of the upper abdomen, which is crucial to complete staging. If present, ascites should be collected and sent for cytologic evaluation. If no ascites is noted, cytologic washings of the pelvis, both paracolic gutters, and the diaphragm should be obtained. Laparoscopic surgical management of ovarian cancer is technically possible, but is not considered prudent by many authorities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=see_link&amp;anchor=H12#H12\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Use of laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pelvis and abdomen are then explored. An oophorectomy, cystectomy, resection of a solid mass, or salpingoophorectomy is performed. The choice of procedure depends upon whether the lesion is benign or malignant and whether the size and location of the lesion allows the surgeon to save some normal ovarian tissue. The specimen is then sent for intraoperative frozen section pathology consultation. Confirmation of the diagnosis should be obtained prior to completion of definitive surgical staging and treatment. In general, salpingo-oophorectomy is the minimum surgical resection performed for malignant lesions since ovarian lymphatics may spread cancer cells to the fallopian tube.",
"   </p>",
"   <p>",
"    If disease appears limited to the pelvis, directed or random peritoneal biopsies are performed, including both paracolic gutters, posterior cul-de-sac, sidewalls, vesicouterine fold, and the diaphragm. If adhesions are present, these should also be sent for histologic review. Omentectomy and appendectomy are performed. It is important to adequately sample pelvic and para-aortic nodes; however, a complete lymphadenectomy is not necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=see_link&amp;anchor=H17#H17\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Exploratory laparotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fertility-preserving surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of a malignant OGCT is confirmed by frozen section, removal of the uterus, both ovaries, and fallopian tubes is suggested for women who have completed childbearing. However, preservation of fertility is often desired since these tumors tend to occur in younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/3\">",
"     3",
"    </a>",
"    ]. Unilateral salpingo-oophorectomy with preservation of a normal-appearing uterus and contralateral ovary is an appropriate procedure in such cases. Even after chemotherapy, at least 80 percent of these women will resume normal menstrual function, and those who become pregnant appear to have no increase in pregnancy complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Gonadal function'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H42\">",
"     'Diagnosis and treatment in pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The ipsilateral fallopian tube is removed because of the rich lymphovascular connections between the tube and ovary. Oncologic outcomes are not compromised by conservative surgery, even in the face of bulky metastatic disease elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/6-12\">",
"     6-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the contralateral ovary appears grossly normal, it should be left undisturbed as routine biopsy commonly leads to peritoneal adhesions which could impair future fertility. The risk of occult contralateral ovarian involvement is greatest with dysgerminomas and likely approaches ten percent. Thus, for women with dysgerminomas, some surgeons routinely perform a wedge biopsy of a normal-appearing contralateral ovary. However, this practice is not universally accepted as these tumors are particularly sensitive to chemotherapy and salvage rates are high. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=see_link&amp;anchor=H21#H21\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Dysgerminoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unnecessary surgery on normal ovaries should be avoided because postoperative adhesions are common and can impair fertility. Another important point is that assisted reproductive technologies enable women with a uterus but no ovaries to become pregnant using an egg donor or their own cryopreserved fertilized",
"    <span class=\"nowrap\">",
"     eggs/ovarian",
"    </span>",
"    <span class=\"nowrap\">",
"     tissue/oocytes,",
"    </span>",
"    and enable women with an ovary but no uterus to serve as an egg donor for a pregnancy fertilized in vitro by their partner and then carried by a gestational surrogate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14425?source=see_link\">",
"     \"Overview of treatment of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initial cytoreduction for advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;If advanced disease is encountered at initial exploration, cytoreductive surgery should be attempted, following the same principles as established for advanced EOC. As much tumor should be resected as is technically feasible and safe. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=see_link&amp;anchor=H25#H25\">",
"     \"Epithelial ovarian cancer: Initial surgical management\", section on 'Cytoreduction procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the rarity of malignant OGCTs, the benefit of cytoreductive surgery is less well established than with EOC. However, surgical debulking of large tumor masses plays a central role in the upfront treatment of OGCTs. Despite the sensitivity of OGCTs to platinum-based chemotherapy, tumor volume is one of the most important prognostic factors for outcome. In most clinical series, prognosis is worse for women with metastatic or incompletely resected disease (",
"    <a class=\"graphic graphic_table graphicRef79165 \" href=\"mobipreview.htm?42/24/43404\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although randomized trials have not been conducted, there is indirect evidence that patients with malignant OGCTs who have optimally debulked disease (ie, all areas of residual disease less than 2 cm) have a higher complete remission rate from chemotherapy and better long-term outcomes than those with bulky unresectable disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early trial from the Gynecologic Oncology Group (GOG), the likelihood of disease progression after postoperative chemotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"       dactinomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (VAC) was significantly higher in patients who had incompletely as compared to completely resected disease at the time of primary surgery (68 versus 28 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent GOG trial examined the benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      (PVB) chemotherapy followed by restaging laparotomy in 111 women with advanced (stage II to IV, (",
"      <a class=\"graphic graphic_table graphicRef51205 \" href=\"mobipreview.htm?14/43/15038\">",
"       table 1",
"      </a>",
"      )) or recurrent malignant OGCTs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/14\">",
"       14",
"      </a>",
"      ]. Eighty-nine had initial cytoreductive surgery, which was recommended but not mandated. Patients who had tumors other than dysgerminoma and clinically nonmeasurable disease after initial surgery had a significantly greater chance of remaining progression-free than those with measurable disease (65 versus 34 percent).",
"     </li>",
"     <li>",
"      Optimal debulking may be more critical for nondysgerminoma tumors. This was shown in a case series of 33 patients with malignant OGCT, 13 of whom had bulky (&gt;10 cm) residual tumor after primary surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/15\">",
"       15",
"      </a>",
"      ]. All 11 patients with dysgerminoma achieved a complete sustained remission after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (BEP), regardless of the size of the postsurgery residual disease. Four of six patients with bulky nondysgerminomatous OGCTs were complete responders to chemotherapy, three sustained long-term. In contrast, 15 of 16 nonbulky nondysgerminomatous OGCTs achieved a complete response to chemotherapy, which was durable in 14 cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, the majority of women with OGCT undergo maximal surgical cytoreduction before starting chemotherapy. The central role that upfront surgery plays in OGCTs is in direct contrast to testicular cancer, where surgery is typically reserved for residual masses that remain after chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38425?source=see_link\">",
"     \"Surgical management of advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the importance of upfront surgical debulking, the surgeon should keep in mind the sensitivity of these tumors to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy when aggressive resection of metastatic disease is considered, particularly in patients with dysgerminomas. With modern cisplatin-based adjuvant chemotherapy, approximately 80 percent of patients who present with advanced disease will be long-term survivors, even if they have residual disease remaining after cytoreductive surgery (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Treatment of advanced disease'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/16-20\">",
"     16-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of surgical management are the same for all malignant OGCTs. Surgery is needed for diagnosis, complete surgical staging, and definitive treatment. Because most women with malignant OGCTs are young and wish to preserve future childbearing capacity, we recommend unilateral salpingo-oophorectomy with preservation of the uterus and the contralateral ovary if these organs appear normal. We suggest total abdominal hysterectomy and bilateral salpingo-oophorectomy in women who have completed childbearing.",
"   </p>",
"   <p>",
"    For patients with advanced tumors, optimal cytoreductive surgery improves outcomes, particularly for nondysgerminomatous tumors. However, the benefits and risks of aggressive cytoreductive maneuvers for metastatic disease must be carefully weighed for these chemotherapy sensitive tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the greatest therapeutic successes in adult oncology has been the development of effective chemotherapy for testicular germ cell tumors. Because of remarkable treatment advances that began in the 1970s with the introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , testicular cancer has become one of the most curable solid neoplasms. Even for men who present with advanced disease, long-term relapse-free survival can be achieved in 90 percent of those who have \"favorable risk\" features and by 50 to 60 percent of those with poor prognostic features (eg, nonpulmonary visceral metastases, very high serum tumor marker levels). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Applying the same",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination chemotherapy regimens used for testicular cancer to OGCTs has dramatically improved overall prognosis. At least 90 percent of patients with early stage OGCT, and approximately 75 to 80 percent of those with advanced disease are long-term survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/14,16-31\">",
"     14,16-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, the first regimen used successfully for the treatment of advanced OGCTs was",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (VAC); however, the number of long-term survivors was under 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/13,32\">",
"     13,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     PVB and BEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The experience gained with treatment of testicular GCTs led to the use of platinum-based regimens for OGCTs. The PVB combination (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ) was initially studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/14,23-25\">",
"     14,23-25",
"    </a>",
"    ]. In the largest prospective study of PVB in 89 patients with stage II to IV nondysgerminomatous OGCTs, 47 (53 percent) remained progression-free, while successful salvage therapy resulted in a 70 percent four-year overall survival rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Later trials in men with testicular cancer demonstrated better tolerability (less neurologic toxicity, abdominal pain, and constipation) and superior efficacy (at least in the setting of bulky disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/26\">",
"     26",
"    </a>",
"    ]) when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    was substituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    (BEP, (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"mobipreview.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    In contemporary series of women and girls with OGCT, long-term survival rates with surgery followed by adjuvant BEP are 95 to 100 percent for early stage nondysgerminomatous tumors and 75 to 80 percent for those with advanced disease at presentation (",
"    <a class=\"graphic graphic_table graphicRef79165 \" href=\"mobipreview.htm?42/24/43404\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/16,17,27-30,33\">",
"     16,17,27-30,33",
"    </a>",
"    ]. Results are even more favorable for ovarian dysgerminomas, regardless of stage at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Management of dysgerminoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the largest trial of BEP from the GOG, 93 patients with completely resected stage I, II or III nondysgerminomatous OGCTs received three courses of postoperative BEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/27\">",
"     27",
"    </a>",
"    ]. Overall, 91 were alive and disease-free, 89 continuously after BEP, and two others who had small foci of immature teratoma at second-look laparotomy remained clinically free of recurrence with follow-up. Two patients developed a treatment-related hematologic secondary malignancy (see",
"    <a class=\"local\" href=\"#H41\">",
"     'Secondary malignancies'",
"    </a>",
"    below). &nbsp;",
"   </p>",
"   <p>",
"    Higher than standard doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    do not improve outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Whether a two-drug combination such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus cisplatin (EP) is sufficient is unclear. Experience in testicular cancer suggests that elimination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    from the BEP regimen compromises outcomes. There are no randomized trials comparing EP versus PVB or BEP in OGCT and only limited data suggesting that at least some patients with OGCT may do well with EP alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, despite the lack of randomized trials directly comparing BEP with VAC, PVB, or EP in women with OGCT, BEP has emerged as the preferred regimen both for adjuvant treatment and for women with advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Can carboplatin be substituted for cisplatin?",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    is associated with less ototoxicity and neurotoxicity (but more myelosuppression) than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . In many but not all tumor types, carboplatin can be substituted for cisplatin without sacrificing efficacy (eg, EOC but not testicular germ cell tumors). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\", section on 'Is there a role for carboplatin?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link&amp;anchor=H760222525#H760222525\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Alternative doses and schedules'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The available data, much of it obtained in children with GCTs, suggest that in contrast to testicular GCTs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    may represent an acceptable therapeutic alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    for the treatment of OGCTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 137 children with extracranial GCTs (recurrent stage I disease and all other patients) received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 2),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (120",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 through 3), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 3), every three to four weeks for two courses beyond clinical remission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/18\">",
"       18",
"      </a>",
"      ]. The median number of chemotherapy courses was five (range, three to eight). With a median follow-up of 53 months, five-year survival and event-free survival rates were 91 and 88 percent, respectively. No patient had significant renal toxicity and only one had severe deafness (as a result of a middle ear hemorrhage). These rates compare favorably with other reports of ototoxicity and nephrotoxicity in patients receiving BEP for GCTs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=see_link\">",
"       \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"      </a>",
"      .) On the other hand, carboplatin-containing regimens are more myelotoxic.",
"     </li>",
"     <li>",
"      Favorable long-term outcomes with a similar regimen (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 2,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 through 3, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 3) were also noted in a series of 23 consecutive children with malignant germ cell tumors (15 females, six primary to the ovary, 19 stage III or IV) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/37\">",
"       37",
"      </a>",
"      ]. With median 58 month follow-up, event-free and overall survival rates were 87 and 91 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these favorable reports, the majority of treatment guidelines still recommend BEP as the standard chemotherapy regimen for OGCT, both for adjuvant treatment and in the setting of advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/31,38\">",
"     31,38",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"      Carboplatin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"      etoposide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"      bleomycin",
"     </a>",
"    </span>",
"    could be considered in a patient with preexisting neuropathy or renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Management of early chemotherapy-related toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women who undergo treatment with BEP develop alopecia; transient myelosuppression, thrombocytopenia, and mucocutaneous toxicity are also common during therapy.",
"   </p>",
"   <p>",
"    Following each course of chemotherapy, the hematologic nadir will generally occur in week two or three and may extend into the beginning of the subsequent cycle. An important point that cannot be overemphasized is that low blood cell counts at the beginning of a scheduled subsequent course of chemotherapy do not mandate dose reductions or treatment delays unless the previous cycle was complicated by febrile neutropenia or some other significant clinical event. Full doses should be administered at the scheduled time, regardless of the white blood cell count; the curative potential of systemic chemotherapy may otherwise be compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of recombinant hematopoietic growth factors on the management of the myelosuppressive complications of these regimens is not precisely defined. Since most patients will not develop neutropenic fever or infection, hematopoietic growth factors will be unnecessary for most patients. However, their use is appropriate as an alternative to dose reduction for patients with a prior episode of febrile neutropenia, unusually ill patients (who may be at higher risk of myelosuppression) or those who have received prior radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neutropenia and other treatment-related toxicities from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based therapy are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=see_link\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Risk stratification and selection of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another point of difference between treatment of ovarian and testicular GCTs is that for men with testicular cancer, initial chemotherapy is selected according to histology and the estimated risk of disease relapse (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26070?source=see_link\">",
"     \"Management of stage I nonseminomatous germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24852?source=see_link\">",
"     \"Risk stratification of metastatic testicular germ cell tumors\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard adjuvant chemotherapy for men with clinical stage I seminoma is two cycles of single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ; alternative management strategies include surveillance or radiation therapy (RT).",
"     </li>",
"     <li>",
"      Standard adjuvant chemotherapy for adult men with a clinical stage I nonseminomatous germ cell tumor (NSGCT) is two cycles of adjuvant BEP; acceptable alternatives include retroperitoneal lymph node dissection or surveillance.",
"     </li>",
"     <li>",
"      Men with advanced \"good risk\" seminoma or NSGCT receive three courses of BEP, while for those with intermediate-risk or poor-risk disease (bulky tumor, liver or brain metastases, very high levels of serum tumor markers at presentation), four cycles of BEP is standard.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the concept of risk stratification in the selection of chemotherapy is not well developed for OGCTs, probably because of their rarity. The recommended approach for both early stage and more advanced OGCTs is postoperative chemotherapy with three or four courses of standard BEP, with the exception of stage I grade 1 immature teratomas and stage IA dysgerminomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/40\">",
"     40",
"    </a>",
"    ]. With these exceptions, no group of OGCTs has been defined that has a sufficiently high cure rate to warrant less intensive therapy.",
"   </p>",
"   <p>",
"    Surveillance is viewed by some as an acceptable alternative for selected patients with stage IA nondysgerminomatous GCTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/40\">",
"     40",
"    </a>",
"    ]. However, this has not been widely adopted as a standard approach. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Surveillance for other stage IA tumors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ongoing studies are addressing prognostic factors that might permit risk stratification for future treatment assignment in OGCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/33,36,41,42\">",
"     33,36,41,42",
"    </a>",
"    ]. As an example, the importance of stage and tumor markers was addressed in an analysis of 148 women with malignant OGCT, 113 of whom received platinum-based chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/33\">",
"     33",
"    </a>",
"    ]. Five-year survival rates were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage IC disease (or stage I disease with",
"      <span class=\"nowrap\">",
"       persistent/increasing",
"      </span>",
"      tumor markers) &mdash; 100 percent",
"     </li>",
"     <li>",
"      Stage II &mdash; 85 percent",
"     </li>",
"     <li>",
"      Stage III &mdash; 79 percent",
"     </li>",
"     <li>",
"      Stage IV &mdash; 71 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who had elevations of both beta-hCG and AFP were almost five times more likely to die of their disease compared to those with initially normal levels of both markers (one-year survival 50 versus 90 percent, respectively).",
"   </p>",
"   <p>",
"    An unanswered clinical question is whether the poor prognosis associated with these factors can be reversed by altering the initial treatment strategy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fertility preservation during chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotoxic cytotoxic chemotherapy often results in premature ovarian failure and infertility, which are major quality of life concerns. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only established method for preservation of child-bearing potential in women at risk of gonadal failure is embryo cryopreservation. This technique should be offered to all eligible patients. When embryo cryopreservation is not feasible, women should be informed about the experimental technique of cryopreservation of oocytes or ovarian tissue. However, these techniques are not widely available, investigational, and their true efficiency is unknown. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the lack of randomized trials, BEP (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"mobipreview.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    ) has emerged as the preferred regimen both for adjuvant treatment and for women with advanced OGCT. Whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    -based regimens are similarly effective remains controversial; treatment guidelines from the National Comprehensive Cancer Network (NCCN) recommend BEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/38\">",
"     38",
"    </a>",
"    ]. Nevertheless,",
"    <span class=\"nowrap\">",
"     carboplatin/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"      etoposide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"      bleomycin",
"     </a>",
"    </span>",
"    could be considered in a patient with preexisting neuropathy or renal disease.",
"   </p>",
"   <p>",
"    Full doses of all of the component drugs should be administered at the scheduled time, regardless of the white blood cell count; the curative potential of systemic chemotherapy may otherwise be compromised. Low blood cell counts at the beginning of a scheduled subsequent course of chemotherapy do not mandate dose reductions or treatment delay. If the previous cycle was complicated by febrile neutropenia or some other significant clinical event, the administration of hematopoietic growth factors during subsequent cycles is warranted in order to avoid dose reduction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link&amp;anchor=H523774290#H523774290\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Secondary prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=see_link&amp;anchor=H523774233#H523774233\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Secondary prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF NONDYSGERMINOMA TUMORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy for stage I disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, a high percentage of patients with early stage, completely resected endodermal sinus tumors, embryonal carcinoma, nongestational choriocarcinoma, high-grade immature teratoma, and mixed tumors containing these elements relapsed and died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/9\">",
"     9",
"    </a>",
"    ]. Small clinical series and a prospective uncontrolled trial from the GOG suggest that over 90 percent of such patients remained progression-free with the addition of adjuvant platinum-based combination chemotherapy to surgery (",
"    <a class=\"graphic graphic_table graphicRef79165 \" href=\"mobipreview.htm?42/24/43404\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/9,11,16-20,27\">",
"     9,11,16-20,27",
"    </a>",
"    ]. In the GOG trial, described above, no patient with stage I disease recurred after three cycles of BEP (see",
"    <a class=\"local\" href=\"#H9\">",
"     'PVB and BEP'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly used regimen is three courses of BEP (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"mobipreview.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    ), although the optimal number of courses has not been the subject of any randomized trial. As noted above, whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    can be safely substituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is uncertain. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend BEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment should be started as soon after surgery as is feasible, particularly for an endodermal sinus or embryonal carcinoma, or a mixed tumor containing these elements. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ideally, treatment should be started within 7 to 10 days of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/19\">",
"     19",
"    </a>",
"    ]. As noted above, full doses should be administered at the scheduled time, regardless of the white blood cell count; the curative potential of systemic chemotherapy may otherwise be compromised. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Management of early chemotherapy-related toxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Surveillance as an alternative to chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of chemotherapy (particularly late effects, (see",
"    <a class=\"local\" href=\"#H39\">",
"     'Late effects of chemotherapy'",
"    </a>",
"    below)), and the ability to successfully salvage relapsed patients with platinum-based chemotherapy has prompted consideration of observation alone in subgroups of women and girls with completely surgically staged stage I (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"mobipreview.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ) disease. The use of this approach for stage I dysgerminomas is discussed below (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Management of dysgerminoma'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Stage I immature teratoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immature solid teratomas are the only OGCT that are histologically graded. Grade (ranging from 1 [well differentiated] to 3 [poorly differentiated]) is based upon the proportion of tissue containing immature neural elements. In most, but not all series, tumor grade correlates with the risk for extraovarian spread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=see_link\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is generally agreed that unilateral salpingo-oophorectomy alone is adequate treatment for stage IA grade 1 unruptured immature teratomas, since outcomes are favorable with surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/39,40,44\">",
"     39,40,44",
"    </a>",
"    ]. However, whether adjuvant chemotherapy improves outcomes for patients with resected stage IA grade 2 or 3 immature teratomas is controversial. Several reports note successful management of these patients with surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/39,40,44\">",
"     39,40,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest series, from the Pediatric Oncology and Children's Cancer Groups, included 73 children with immature teratoma (44 ovarian origin, 18 grade 1, 18 grade 2, and 8 grade 3) who had surgery followed by surveillance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/44\">",
"       44",
"      </a>",
"      ]. While 82 percent of the tumors were grade 1 or 2, 12 of 13 tumors with foci of yolk sac tumor (an adverse prognostic feature [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/45\">",
"       45",
"      </a>",
"      ]) were grade 2 or 3.",
"      <br/>",
"      <br/>",
"      At a median follow-up of 35 months, the overall three-year event-free survival rates for all patients and those with ovarian teratomas were 93 and 98 percent, respectively. Of the 13 girls with immature ovarian teratoma and microscopic foci of yolk sac tumor, only one developed recurrent disease, and she was successfully salvaged with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy.",
"     </li>",
"     <li>",
"      Four other studies report a total of 51 patients with stage I, grade 2 or 3 immature teratoma treated with close observation after surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/39,40,46,47\">",
"       39,40,46,47",
"      </a>",
"      ]. A total of six patients recurred, and all were successfully salvaged with surgery with or without chemotherapy; all patients were alive and disease-free at least follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the view that surgery followed by close surveillance is reasonable for stage IA, grade 2 or 3 immature teratomas, even with microscopic yolk sac components. However, this is not yet a standard approach, and most treatment guidelines recommend adjuvant chemotherapy for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Surveillance for other stage IA tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected completely surgically-staged women and girls with nondysgerminomatous stage IA ovarian germ cell tumors (OGCTs) may be adequately treated with surgery alone; this approach is more commonly used by pediatric oncologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/40,48,49\">",
"     40,48,49",
"    </a>",
"    ]. The success of this approach in adults was shown in a series of 24 women (nine dysgerminoma, nine immature teratoma and six endodermal sinus tumor) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/40\">",
"     40",
"    </a>",
"    ]. All women underwent surgery followed by periodic clinical, serologic and radiologic surveillance, and second-look surgery for patients enrolled after 1982. Five-year rates of disease-free and overall survival were 68 and 95 percent, respectively. Three of the eight patients who required chemotherapy for disease recurrence or a second OGCT had a grade 2 immature teratoma, and five had dysgerminoma; none had endodermal sinus tumors. All but one were successfully salvaged with chemotherapy.",
"   </p>",
"   <p>",
"    Additional information about the outcomes of surveillance are expected from a trial conducted by the Children's Oncology Group (COG), which prospectively tested the strategy of surgery alone followed by observation in children and adolescents (up to age 21) with completely resected low-risk (stage I) malignant OGCTs, including mixed ovarian dysgerminomas with yolk sac, embryonal, or choriocarcinoma components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/50\">",
"     50",
"    </a>",
"    ]. Enrollment to this trial is complete, and maturation of the data is awaited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral oophorectomy alone is adequate treatment for stage I grade 1 immature teratomas. We suggest adjuvant chemotherapy (three courses of BEP, (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"mobipreview.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    )) for patients with grade 2 and 3 immature teratomas due to the limited experience with surgery alone.",
"   </p>",
"   <p>",
"    Until further data become available, we also suggest adjuvant therapy (three cycles of platinum-based chemotherapy) for adult women with resected stage IA nondysgerminomatous OGCT. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment of advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard treatment for all patients with stage II to IV malignant OGCT and nondysgerminoma histology (including immature teratoma) is maximal cytoreduction followed by at least four courses of BEP (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"mobipreview.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    ), given at full dose and on schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/38\">",
"     38",
"    </a>",
"    ]. Even for incompletely resected advanced disease, long-term survival can be expected in approximately 60 to 80 percent of cases (",
"    <a class=\"graphic graphic_table graphicRef79165 \" href=\"mobipreview.htm?42/24/43404\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/9,11,14,16-20,24,25,31,33,51\">",
"     9,11,14,16-20,24,25,31,33,51",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H9\">",
"     'PVB and BEP'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    As with early stage disease, the optimal number of chemotherapy cycles is not defined. Most recommend four to six cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/31,38\">",
"     31,38",
"    </a>",
"    ]. We administer four courses of BEP for patients with completely resected stage II or III disease, and six cycles for those with gross residual or stage IV disease. The COG is prospectively studying a reduction in the number of courses of chemotherapy from four to three in children and adolescents with intermediate-risk (stage II or III) completely resected malignant OGCTs, and a reduction in the number of days that chemotherapy is administered per cycle from five to three. Eligible patients (up to age 21) should be encouraged to enroll [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in the adjuvant setting, whether or not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    can be safely substituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in patients with advanced disease remains uncertain, although preliminary data are encouraging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/18,37\">",
"     18,37",
"    </a>",
"    ]. Treatment guidelines from the National Comprehensive Cancer Network (NCCN) suggest BEP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If they are initially elevated, serial levels of serum tumor markers should be followed during chemotherapy to monitor disease status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=see_link&amp;anchor=H7#H7\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Tumor markers'",
"    </a>",
"    .) Persistently elevated or rising levels of tumor markers during therapy indicate the need for salvage chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/38\">",
"     38",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H30\">",
"     'Posttreatment surveillance'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Occasionally, patients with",
"    <strong>",
"     immature",
"    </strong>",
"    teratomas will have a persistent mass seen on imaging after chemotherapy. Resection is advisable. At exploration, mature tissue types may be found which do not require further chemotherapy. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Role of second-look surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Malignant transformation in mature teratomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are rare malignancies that arise in mature teratomas, such as thyroid cancer, squamous cell carcinoma, and carcinoid. The rarity of these tumors precludes any uniform management suggestions, other than attempting complete cytoreductive surgery. Chemotherapy should be geared toward the transformed component. Radioactive iodine (I-131) ablation may be used for functioning thyroid malignancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF DYSGERMINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian dysgerminoma is the female equivalent of testicular seminoma. As in the testicle, dysgerminomas differ from other malignant OGCTs in several ways: they are more likely to be localized to the ovary at diagnosis (approximately two-thirds of cases are stage IA, (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"mobipreview.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    )), bilateral ovarian involvement is more common (10 to 15 percent), they are more likely to spread in a predictable fashion, and they are more sensitive to radiation therapy (RT). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the treatment of testicular germ cell tumors\", section on 'Overview of treatment approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Surveillance for stage IA disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes from surveillance for completely resected stage IA disease are excellent. Although 15 to 25 percent of such patients will recur, virtually all of these women will be successfully salvaged by platinum-based chemotherapy or RT (",
"    <a class=\"graphic graphic_table graphicRef78392 \" href=\"mobipreview.htm?20/19/20795\">",
"     table 5",
"    </a>",
"    ). Long-term cure rates are &gt;90 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with completely resected stage IB or higher ovarian dysgerminoma, as well as for those with more advanced, unresectable disease, platinum-based combination chemotherapy almost always prevents recurrence, and most patients retain fertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/14,16,22,51-53\">",
"     14,16,22,51-53",
"    </a>",
"    ]. In one representative series of 26 patients with pure ovarian dysgerminoma (54 percent stage IIIC or IV, (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"mobipreview.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    )), 25 (96 percent) remained continuously disease-free following three to six cycles of BEP chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/52\">",
"     52",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -based chemotherapy has become the adjuvant treatment of choice for patients with stage IB or higher dysgerminoma, even when fertility is not an issue (see",
"    <a class=\"local\" href=\"#H40\">",
"     'Gonadal function'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The most commonly used chemotherapy regimen is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (BEP) (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"mobipreview.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    ). The optimal number of cycles has not been established in randomized trials. Due to the sensitivity of dysgerminomas to cisplatin, we suggest three courses for adjuvant therapy of completely resected stage I disease, and four courses for those with more advanced stage disease.",
"   </p>",
"   <p>",
"    Subsequent data from the Gynecologic Oncology Group (GOG) suggest a similar degree of benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/54\">",
"     54",
"    </a>",
"    ]. Three 28-day courses of carboplatin (400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) plus etoposide (120",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 2, and 3) were administered to 42 patients with completely resected stage IB-III dysgerminoma (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"mobipreview.htm?14/43/15038\">",
"     table 1",
"    </a>",
"    ). With a median follow-up of 7.8 years, no patient had a disease recurrence, although one died of a presumably unrelated lung adenocarcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Postoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative RT has been a standard treatment for women with resected dysgerminoma of any stage, particularly those with large (&gt;10 cm) or incompletely resected tumors. Due to the extreme radiosensitivity of these tumors, moderate dose abdominal RT (25 to 30 Gy in 20 to 25 fractions plus a fractionated 10 Gy boost to areas of gross disease) was effective, and less toxic than the conventional doses used for other gynecologic malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/55\">",
"     55",
"    </a>",
"    ]. Cure rates using this approach were over 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/56-59\">",
"     56-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, concerns about the long-term adverse effects of RT (particularly infertility), coupled with the evolution of effective platinum-based chemotherapy regimens and the fact that up to 40 percent of women with incompletely resected dysgerminomas will recur after RT alone, have led to a shift away from its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest postoperative surveillance rather than RT for women with completely surgically-staged stage IA dysgerminoma, regardless of primary tumor size.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -based chemotherapy is preferred over RT for those with higher stage disease. We suggest three courses of BEP for women with completely resected stage I disease and four courses for all others.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    may be equally effective for patients with completely resected disease, although we still use BEP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ROLE OF SECOND-LOOK SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"second-look\" laparotomy most often refers to surgical reexploration of asymptomatic women diagnosed with epithelial ovarian cancer (EOC) who have no clinical evidence of tumor following initial surgery and completion of a planned course of systemic chemotherapy. The term is also sometimes used to describe a second",
"    <span class=\"nowrap\">",
"     laparotomy/laparoscopy",
"    </span>",
"    for cytoreduction of known",
"    <span class=\"nowrap\">",
"     recurrent/residual",
"    </span>",
"    disease to improve the response to subsequent chemotherapy or to relieve symptomatic disease. In this context, the term \"secondary cytoreduction\" is also acceptable.",
"   </p>",
"   <p>",
"    Second-look procedures were initially introduced into the management of EOC to establish an end point for the number of chemotherapy cycles administered to women with an apparent clinical complete response. However, the inability to demonstrate better survival in women undergoing second-look surgery has tempered initial enthusiasm for this approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25847?source=see_link\">",
"     \"Epithelial ovarian cancer: Second look surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with OGCTs, the main utility of second-look surgery is for those who have an isolated focus of residual mass after completion of first-line chemotherapy. Resection and histologic study may show residual malignant tumor, which should prompt an alteration in the chemotherapy regimen. For patients whose tumors contained elements of immature teratoma, residual mature teratoma may be found. Although mature teratomas are benign, the rationale for complete resection of any residual mature teratoma includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unresected mature teratoma may grow and become surgically unresectable, potentially compromising vital organ function (the growing teratoma syndrome) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/60\">",
"       60",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Besides being a source for late recurrence, a mature teratoma may very rarely degenerate into a sarcoma or adenocarcinoma, a process termed malignant transformation. These histologies tend to be resistant to standard chemotherapy used for OGCTs, but may respond to chemotherapy directed towards the predominant malignant cell type. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/40/5770?source=see_link&amp;anchor=H11#H11\">",
"       \"Anatomy and pathology of testicular tumors\", section on 'Teratoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefit of salvage surgery has been addressed in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outcomes from second-look surgery were described in a study from the Gynecologic Oncology Group (GOG) of 72 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy for advanced, incompletely resected malignant OGCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/61\">",
"       61",
"      </a>",
"      ]. At secondary surgery, 45 of the 48 women without teratomatous elements had no tumor, while three had persistent endodermal sinus tumor or embryonal carcinoma. All three of the latter patients died despite further treatment. Of the 24 patients who had teratomatous elements in their primary tumor, 16 had mature teratoma at second-look, which in 7 was bulky or progressive. Fourteen of the total 16 and six of the seven women with bulky residual teratoma remain disease-free after surgical resection.",
"     </li>",
"     <li>",
"      A second series included 20 patients (eight with immature teratoma) who underwent salvage surgery for chemorefractory OGCT over a 17-year period at a single institution, followed in almost all cases by postoperative chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/62\">",
"       62",
"      </a>",
"      ]. Nineteen remained without evidence of disease recurrence several years posttreatment, and there was a trend toward better survival for those who had residual disease &lt;2 cm.",
"     </li>",
"     <li>",
"      The importance of histology and the completeness of salvage surgery was studied in 34 women who had chemorefractory OGCTs at a single institution over a 13-year period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/63\">",
"       63",
"      </a>",
"      ]. There were two dysgerminomas, seven immature teratomas, 22 endodermal sinus tumors (16 pure, six mixed type), two embryonal carcinomas and one mixed",
"      <span class=\"nowrap\">",
"       OGCT/sex",
"      </span>",
"      cord stromal tumor. All 34 underwent postsurgical salvage chemotherapy.",
"      <br/>",
"      <br/>",
"      Three- and five-year survival rates among those who were rendered macroscopically disease-free or who had residual tumor &le;1 cm after surgical salvage were 80 and 61 percent; the corresponding values for women who had postoperative residual disease &gt;1 cm were 21 and 14 percent, respectively. Patients with dysgerminoma and immature teratoma had significantly better outcomes than did those with other histologies (five-year survival 55 versus 23 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Second-look surgery is",
"    <strong>",
"     not",
"    </strong>",
"    indicated in women with initially completely resected disease, or in those with persistently elevated serum tumor markers at the completion of therapy. Institution of salvage chemotherapy is the appropriate intervention if tumor markers remain elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/64\">",
"     64",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H36\">",
"     'Recurrent or persistent disease'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postchemotherapy second-look laparotomy is recommended for a small subset of patients who have a teratoma component in an initially incompletely resected primary tumor if the serum tumor markers have normalized. It is not necessary for patients with initially completely resected OGCT, or for those patients with advanced OGCT that does not contain teratoma.",
"   </p>",
"   <p>",
"    In general, patients with persistently elevated serum tumor markers following initial chemotherapy require salvage chemotherapy rather than a second-look laparotomy. A rising level of beta-human chorionic gonadotropin (HCG) requires that pregnancy be ruled out",
"    <strong>",
"     before",
"    </strong>",
"    chemotherapy is instituted. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Tumor markers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most recurrences develop within two years of initial therapy, although as with testicular seminomas, dysgerminomas may recur later (after ten years or more).",
"   </p>",
"   <p>",
"    As with testicular GCTs, posttreatment surveillance with serial assays of those tumor markers that were initially elevate, and clinical surveillance to detect recurrent or persistent disease are recommended at regular intervals after treatment of OGCT; there is less agreement as to the role of radiographic surveillance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9943?source=see_link&amp;anchor=H7#H7\">",
"     \"Posttreatment follow-up for men with testicular germ cell tumors\", section on 'Guidelines for follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many OGCTs produce tumor products (alpha fetoprotein [AFP], human chorionic gonadotropin [hCG], and",
"    <span class=\"nowrap\">",
"     /or",
"    </span>",
"    lactate dehydrogenase [LDH]) that can be measured in the serum. Their presence provides a highly sensitive and specific marker for the presence of certain histologic components (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"mobipreview.htm?24/4/24653\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=see_link&amp;anchor=H7#H7\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Tumor markers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serial assay of these markers is useful for posttreatment follow-up, even if tumor markers were not initially elevated. Persistently elevated or rising serum levels imply the presence of persistent or recurrent disease. However, several caveats must be kept in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Undetectable tumor marker levels do not necessarily mean the patient is disease-free, particularly if she has a mixed germ cell tumor.",
"     </li>",
"     <li>",
"      Growing teratoma syndrome is generally unaccompanied by tumor marker elevation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum levels of tumor markers may underestimate the presence and extent of a recurrent immature teratoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/65,66\">",
"       65,66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Dysgerminomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor markers are of greatest utility for nondysgerminomatous tumors. For patients with dysgerminoma, there are no tumor markers that reliably serve as indicators of disease recurrence, with the possible exception of lactate dehydrogenase (LDH). Recommendations for which tumor markers to assay, and how often they should be assayed in posttreatment surveillance for the male counterpart of dysgerminoma (testicular seminoma) are diverse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, because of the possibility that an occult mixed cell component could have been missed, particularly in those with incompletely resected disease, we routinely assay AFP, LDH and hCG following treatment in these patients, even if they were not initially elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Radiographic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for radiographic surveillance in women with treated OGCTs is unclear. There are no prospective trials testing the utility of radiographic in addition to clinical and tumor marker surveillance. In men with testicular cancer, radiographic follow-up is generally recommended at periodic intervals following treatment, depending on histology and specific treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9943?source=see_link&amp;anchor=H7#H7\">",
"     \"Posttreatment follow-up for men with testicular germ cell tumors\", section on 'Guidelines for follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, guidelines from both the National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) do not recommend routine radiographic surveillance after treatment of ovarian GCT. The SGO guidelines recommend radiographic imaging every two to four months in the first two years only for patients whose tumor markers are not initially elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Pulmonary toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with testicular cancer, physicians caring for long-term survivors of OGCT should be aware of the potential for chemotherapy to adversely affect pulmonary function in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29877892\">",
"    <span class=\"h2\">",
"     Guidelines from expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal posttreatment surveillance strategy has not been established. Several strategies are recommended by different groups, although these represent expert opinion and are not evidence-based:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NCCN guidelines suggest that markers be assayed every two to four months for two years, if they were initially elevated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Guidelines for posttreatment follow-up from the SGO recommend review of symptoms, physical examination, and assay of serum tumor markers every two to four months for the first two years for all patients. Review of symptoms and physical examination are then recommended annually up to and beyond five years for all patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/68\">",
"       68",
"      </a>",
"      ]. Radiographic imaging is recommended every two to four months for the first two years only in patients whose initial tumor marker levels are not elevated. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     RECURRENT OR PERSISTENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, 90 percent of recurrences develop in the first two years after completion of therapy. Relapses occurring after two years (late relapses) tend to be slow growing and relatively chemotherapy resistant, although newer regimens incorporating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    are challenging this dogma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/56/2954?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Late relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Relapse after surgery alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with relapsed disease who were initially treated with surgery alone (stage I dysgerminoma, stage I grade 1 immature teratoma) can be successfully treated with BEP chemotherapy. Long-term survival rates are &gt;90 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Relapse after adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a disease recurrence several months after completion of treatment can be successfully retreated with a platinum-based combination chemotherapy regimen. These patients are managed similarly to men with relapsed or refractory testicular cancer.",
"   </p>",
"   <p>",
"    However, at least some data suggest that long-term disease control will be achieved in only about 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast, approximately 25 percent of men with relapsed platinum-sensitive testicular cancer will achieve a durable remission with standard-dose salvage regimens that contain",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and platinum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/56/2954?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Standard-dose chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Active regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VIP &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      1.2",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      all administered daily for five consecutive days every three weeks",
"     </li>",
"     <li>",
"      VeIP &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      0.11",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for two days,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      1200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days",
"     </li>",
"     <li>",
"      TIP &ndash; four 21-day cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 24 hours on day 1, followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      1500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day on days 2 to 6, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day on days 2 to 6",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of women who have persistent disease (including elevated serum tumor markers) after chemotherapy or who progress within four to eight weeks of completing adjuvant treatment is more difficult. As with testicular cancer, management depends on whether the disease is platinum-sensitive or platinum-resistant (ie, progression of disease either during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy or within four weeks of completing treatment).",
"   </p>",
"   <p>",
"    Results with the above salvage regimens and high-dose chemotherapy are poor in the setting of platinum-refractory disease. New regimens combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    and cisplatin, show some promise in this setting; however, such therapy is primarily palliative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/56/2954?source=see_link&amp;anchor=H196220871#H196220871\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Platinum-refractory disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     LATE EFFECTS OF CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are substantial data regarding late effects of BEP in men with testicular cancer. Among the long-term adverse events reported in men who receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy are renal and gonadal dysfunction, neurotoxicity, cardiovascular toxicity, secondary malignancies, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced pulmonary fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=see_link\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sparse information is available for women with OGCTs. One study compared chronic physical effects and health care utilization of 132 OGCT survivors who were disease-free for at least two years after surgery and platinum-based chemotherapy versus 137 matched controls that were selected from acquaintances of the survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/69\">",
"     69",
"    </a>",
"    ]. Survivors were approximately 10 years post diagnosis, and 87 percent had been treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Survivors were significantly more likely to report a diagnosis of hypertension (17 versus 8 percent), and they had a nonstatistically significant higher rate of hypercholesterolemia (10 versus 4 percent) and hearing loss (5 versus 2 percent). There were no differences in self-reported arthritis, heart, pulmonary, or kidney disease, diabetes, non-OGCT malignancies, anxiety, hearing loss, or eating disorders. From a functional standpoint, survivors were more likely than controls to have numbness and tingling in the hands and feet, tinnitus, Raynaud's symptoms, and nausea elicited by thoughts of chemotherapy. Health care utilization was similar overall, but significantly more survivors reported being denied health insurance (16 versus 4 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Gonadal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important cause of infertility in patients with OGCTs is unnecessary bilateral salpingo-oophorectomy and hysterectomy (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Fertility-preserving surgery'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Although ovarian dysfunction or failure is a risk of platinum-based chemotherapy, most women who receive three or four courses of standard dose therapy will recover normal ovarian function, and childbearing is often preserved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/4-8,14,19,20,52\">",
"     4-8,14,19,20,52",
"    </a>",
"    ]. In a representative series of 71 patients treated with both fertility sparing surgery and combination chemotherapy for OGCT, 62 (87 percent) resumed normal menstruation, and 24 of these women subsequently had 37 offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/5\">",
"     5",
"    </a>",
"    ]. Factors such as older age at initiation of chemotherapy, greater cumulative drug dose, and longer duration of therapy all have an adverse effect on future gonadal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7977?source=see_link\">",
"     \"Overview of fertility and pregnancy in cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Secondary malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important cause of late morbidity and mortality in patients undergoing treatment for GCTs is the development of secondary malignancies, both solid tumors and leukemia.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     Etoposide",
"    </a>",
"    in particular has been implicated in the development of treatment-related leukemias. The risk is dose-related. The incidence of leukemia is &lt;0.5 percent in patients receiving a typical three- or four-cycle course of BEP (cumulative etoposide dose &lt;2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/70\">",
"     70",
"    </a>",
"    ], compared to as much as 5 percent (representing a 336-fold increase in the likelihood of leukemia) in those receiving over 2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the risk of secondary leukemia, risk-benefit analyses have concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    -containing chemotherapy regimens are beneficial in advanced GCTs; one case of treatment-induced leukemia would be expected for every 20 additionally cured patients who receive PEB as compared to PVB. The risk-benefit balance for low risk disease, or for high dose etoposide in the salvage setting, is less clear. This topic is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\", section on 'Second malignancies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND TREATMENT IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;OGCTS often occur in women of reproductive age; therefore, these tumors are one of the more common ovarian malignancies diagnosed in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/72\">",
"     72",
"    </a>",
"    ]. Chemotherapy treatment of OGCTs in pregnant women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19287?source=see_link\">",
"     \"Chemotherapy of ovarian cancer in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant germ cell cancers of the ovary include dysgerminomas (which are analogous to the male testicular seminoma), and nondysgerminomatous tumors, which can be immature teratomas, embryonal cell carcinoma, endodermal sinus (also called yolk sac) tumors, primary ovarian (nongestational) choriocarcinomas, polyembryoma, or mixed germ cell tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/24/33162/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the treatment principles for all types of malignant ovarian germ cell tumor (OGCT) are similar, and include surgery for diagnosis, and complete surgical staging, cytoreductive surgery if advanced disease is present, and adjuvant chemotherapy in most cases (",
"    <a class=\"graphic graphic_table graphicRef55704 \" href=\"mobipreview.htm?0/58/940\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Primary surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most women with OGCTs are young and wish to preserve future childbearing capacity. For these women, we recommend unilateral salpingo-oophorectomy with preservation of the uterus and the contralateral ovary if these organs appear normal (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest total abdominal hysterectomy and bilateral salpingo-oophorectomy for women who have completed childbearing (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Fertility-preserving surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with advanced tumors, we suggest optimal cytoreductive surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, the benefits and risks of aggressive cytoreductive maneuvers for metastatic disease must be carefully weighed for these highly chemotherapy-sensitive tumors. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initial cytoreduction for advanced disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend three cycles of postoperative adjuvant platinum-based combination chemotherapy for nearly all adult women with completely resected stage I ovarian germ cell malignancies (",
"      <a class=\"graphic graphic_table graphicRef55704 \" href=\"mobipreview.htm?0/58/940\">",
"       table 6",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The exceptions, discussed below, are those with stage IA (",
"      <a class=\"graphic graphic_table graphicRef51205 \" href=\"mobipreview.htm?14/43/15038\">",
"       table 1",
"      </a>",
"      ) dysgerminoma or stage IA grade 1 unruptured immature teratoma. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Management of dysgerminoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surgery followed by close surveillance rather than radiation therapy or adjuvant chemotherapy for those with completely surgically staged stage IA dysgerminoma (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Management of dysgerminoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend unilateral salpingo-oophorectomy alone for stage IA grade 1 immature teratomas (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). As noted above, we suggest adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy rather than observation in patients with grade 2 and 3 stage I immature teratomas (",
"      <a class=\"graphic graphic_table graphicRef55704 \" href=\"mobipreview.htm?0/58/940\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Surveillance as an alternative to chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all women with incompletely resected and metastatic (stage II to IV) dysgerminomas and nondysgerminomatous OGCTs, we recommend postoperative",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The recommended regimen and number of courses are outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef55704 \" href=\"mobipreview.htm?0/58/940\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment of advanced disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When chemotherapy is delivered either in the adjuvant setting or for advanced disease, full doses should be administered at the scheduled time, regardless of the white blood cell count. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Management of early chemotherapy-related toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with normalized tumor markers who have residual masses after chemotherapy, we recommend salvage surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We recommend salvage chemotherapy for those with persistently elevated tumor markers at the completion of initial chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We select the salvage regimen based upon whether the disease is platinum-sensitive or platinum-refractory. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/56/2954?source=see_link\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Close posttreatment surveillance is necessary after treatment of all stages of OGCT. Although the optimal surveillance strategy is unknown, we suggest history and physical examination and assay of serum tumor markers (even if normal initially) every three months for two years, then an annual review of symptoms and physical examination up to and beyond five years. &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In keeping with the guidelines from the Society of Gynecologic Oncologists, we only perform radiographic surveillance within the first two years if tumor markers are not elevated initially. Given the risk for late relapse, dysgerminomas require annual follow-up for at least 10 years. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Blaustein's Pathology of the Female Genital Tract, 4th, Blaustein A, Kurman RJ (Eds), Springer-Verlag, 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/2\">",
"      Kumar S, Shah JP, Bryant CS, et al. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol 2008; 110:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/3\">",
"      Mangili G, Sigismondi C, Lorusso D, et al. Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience. Gynecol Oncol 2011; 121:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/4\">",
"      Maltaris T, Boehm D, Dittrich R, et al. Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol 2006; 103:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/5\">",
"      Gershenson DM, Miller AM, Champion VL, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:2792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/6\">",
"      Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 2003; 101:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/7\">",
"      Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer 2000; 89:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/8\">",
"      Zanetta G, Bonazzi C, Cant&ugrave; M, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001; 19:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/9\">",
"      Lai CH, Chang TC, Hsueh S, et al. Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 2005; 96:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/10\">",
"      Peccatori F, Bonazzi C, Chiari S, et al. Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients. Obstet Gynecol 1995; 86:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/11\">",
"      Billmire D, Vinocur C, Rescorla F, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 2004; 39:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/12\">",
"      Zanagnolo V, Sartori E, Galleri G, et al. Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004; 25:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/13\">",
"      Slayton RE, Park RC, Silverberg SG, et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer 1985; 56:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/14\">",
"      Williams SD, Blessing JA, Moore DH, et al. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group. Ann Intern Med 1989; 111:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/15\">",
"      Bafna UD, Umadevi K, Kumaran C, et al. Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int J Gynecol Cancer 2001; 11:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/16\">",
"      Gershenson DM, Morris M, Cangir A, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990; 8:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/17\">",
"      Dimopoulos MA, Papadopoulou M, Andreopoulou E, et al. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. Gynecol Oncol 1998; 70:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/18\">",
"      Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 2000; 18:3809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/19\">",
"      Williams SD. Ovarian germ cell tumors: an update. Semin Oncol 1998; 25:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/20\">",
"      Segelov E, Campbell J, Ng M, et al. Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience. J Clin Oncol 1994; 12:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/21\">",
"      Culine S, Lhomme C, Kattan J, et al. Cisplatin-based chemotherapy in dysgerminoma of the ovary: thirteen-year experience at the Institut Gustave Roussy. Gynecol Oncol 1995; 58:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/22\">",
"      Culine S, Lhomme C, Kattan J, et al. Cisplatin-based chemotherapy in the management of germ cell tumors of the ovary: The Institut Gustave Roussy Experience. Gynecol Oncol 1997; 64:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/23\">",
"      Gershenson DM, Kavanagh JJ, Copeland LJ, et al. Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatin. Cancer 1986; 57:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/24\">",
"      Carlson RW, Sikic BI, Turbow MM, Ballon SC. Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary. J Clin Oncol 1983; 1:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/25\">",
"      Taylor MH, Depetrillo AD, Turner AR. Vinblastine, bleomycin, and cisplatin in malignant germ cell tumors of the ovary. Cancer 1985; 56:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/26\">",
"      Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/27\">",
"      Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol 1994; 12:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/28\">",
"      Rogers PC, Olson TA, Cullen JW, et al. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol 2004; 22:3563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/29\">",
"      Mayordomo JI, Paz-Ares L, Rivera F, et al. Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients. Ann Oncol 1994; 5:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/30\">",
"      Tewari K, Cappuccini F, Disaia PJ, et al. Malignant germ cell tumors of the ovary. Obstet Gynecol 2000; 95:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/31\">",
"      Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med 2005; 50:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/32\">",
"      Gershenson DM, Copeland LJ, Kavanagh JJ, et al. Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide. Cancer 1985; 56:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/33\">",
"      Murugaesu N, Schmid P, Dancey G, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 2006; 24:4862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/34\">",
"      Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 2004; 22:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/35\">",
"      Culine S, Kattan J, Lhomme C, et al. A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary. Gynecol Oncol 1994; 54:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/36\">",
"      Lopes LF, Macedo CR, Pontes EM, et al. Cisplatin and etoposide in childhood germ cell tumor: brazilian pediatric oncology society protocol GCT-91. J Clin Oncol 2009; 27:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/37\">",
"      Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med Pediatr Oncol 2002; 39:163.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/39\">",
"      Bonazzi C, Peccatori F, Colombo N, et al. Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients. Obstet Gynecol 1994; 84:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/40\">",
"      Dark GG, Bower M, Newlands ES, et al. Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 1997; 15:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/41\">",
"      Mitchell PL, Al-Nasiri N, A'Hern R, et al. Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases. Cancer 1999; 85:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/42\">",
"      Mayordomo JI, Paz-Ares L, Diaz-Puente MT, et al. Prognostic factors for women with ovarian germ cell tumors. J Clin Oncol 1994; 12:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/43\">",
"      O'Connor DM, Norris HJ. The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol 1994; 13:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/44\">",
"      Marina NM, Cushing B, Giller R, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. J Clin Oncol 1999; 17:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/45\">",
"      Woodruff JD, Protos P, Peterson WF. Ovarian teratomas. Relationship of histologic and ontogenic factors to prognosis. Am J Obstet Gynecol 1968; 102:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/46\">",
"      Mangili G, Scarfone G, Gadducci A, et al. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol Oncol 2010; 119:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/47\">",
"      Cushing B, Giller R, Ablin A, et al. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group. Am J Obstet Gynecol 1999; 181:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/48\">",
"      Baranzelli MC, Bouffet E, Quintana E, et al. Non-seminomatous ovarian germ cell tumours in children. Eur J Cancer 2000; 36:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/49\">",
"      Baranzelli MC, Flamant F, De Lumley L, et al. Treatment of non-metastatic, non-seminomatous malignant germ-cell tumours in childhood: experience of the \"Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique\" MGCT 1985-1989 study. Med Pediatr Oncol 1993; 21:395.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00053352?term=COG+trial+AGCT0132&amp;rank=1 (Accessed on September 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/51\">",
"      Williams SD, Blessing JA, Hatch KD, Homesley HD. Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. J Clin Oncol 1991; 9:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/52\">",
"      Brewer M, Gershenson DM, Herzog CE, et al. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999; 17:2670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/53\">",
"      Pawinski A, Favalli G, Ploch E, et al. PVB chemotherapy in patients with recurrent or advanced dysgerminoma: a Phase II study of the EORTC Gynaecological Cancer Cooperative Group. Clin Oncol (R Coll Radiol) 1998; 10:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/54\">",
"      Williams SD, Kauderer J, Burnett AF, et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol 2004; 95:496.",
"     </a>",
"    </li>",
"    <li>",
"     Stambaugh MD. Ovary. In: Principles and Practice of Radiation Oncology, 4th, Perez CA, Brady LW, Halperin CA, Schmidt-Ullrich RK (Eds), Lippincott, Williams and Wilkins, Philadelphia 1997. p.1948.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/56\">",
"      Krepart G, Smith JP, Rutledge F, Delclos L. The treatment for dysgerminoma of the ovary. Cancer 1978; 41:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/57\">",
"      De Palo G, Lattuada A, Kenda R, et al. Germ cell tumors of the ovary: the experience of the National Cancer Institute of Milan. I. Dysgerminoma. Int J Radiat Oncol Biol Phys 1987; 13:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/58\">",
"      Teinturier C, Gelez J, Flamant F, et al. Pure dysgerminoma of the ovary in childhood: treatment results and sequelae. Med Pediatr Oncol 1994; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/59\">",
"      Hale GA, Marina NM, Jones-Wallace D, et al. Late effects of treatment for germ cell tumors during childhood and adolescence. J Pediatr Hematol Oncol 1999; 21:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/60\">",
"      Andr&eacute; F, Fizazi K, Culine S, et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer 2000; 36:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/61\">",
"      Williams SD, Blessing JA, DiSaia PJ, et al. Second-look laparotomy in ovarian germ cell tumors: the gynecologic oncology group experience. Gynecol Oncol 1994; 52:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/62\">",
"      Munkarah A, Gershenson DM, Levenback C, et al. Salvage surgery for chemorefractory ovarian germ cell tumors. Gynecol Oncol 1994; 55:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/63\">",
"      Li J, Yang W, Wu X. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients. Gynecol Oncol 2007; 105:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/64\">",
"      Culine S, Lhomme C, Michel G, et al. Is there a role for second-look laparotomy in the management of malignant germ cell tumors of the ovary? Experience at Institut Gustave Roussy. J Surg Oncol 1996; 62:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/65\">",
"      Rezk Y, Sheinfeld J, Chi DS. Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma: a case report and review of the literature. Gynecol Oncol 2005; 96:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/66\">",
"      Busmanis I, Tay SK. Recurrent immature teratoma: lack of correlation between serum level and immunohistochemical detection of serum alpha-fetoprotein. Pathology 1998; 30:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/67\">",
"      Haugnes HS, Aass N, Foss&aring; SD, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009; 27:2779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/68\">",
"      Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/69\">",
"      Matei D, Miller AM, Monahan P, et al. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27:4142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/70\">",
"      Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000; 92:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/71\">",
"      Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/24/33162/abstract/72\">",
"      Novak ER, Lambrou CD, Woodruff JD. Ovarian tumors in pregnancy. An ovarian tumor registry review. Obstet Gynecol 1975; 46:401.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3197 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33162=[""].join("\n");
var outline_f32_24_33162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGING AND PATTERN OF SPREAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRIMARY SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial exploration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fertility-preserving surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initial cytoreduction for advanced disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GENERAL PRINCIPLES OF CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PVB and BEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Can carboplatin be substituted for cisplatin?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Management of early chemotherapy-related toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Risk stratification and selection of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fertility preservation during chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT OF NONDYSGERMINOMA TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Adjuvant chemotherapy for stage I disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Surveillance as an alternative to chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Stage I immature teratoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Surveillance for other stage IA tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment of advanced disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Malignant transformation in mature teratomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MANAGEMENT OF DYSGERMINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Surveillance for stage IA disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Postoperative RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ROLE OF SECOND-LOOK SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Dysgerminomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Radiographic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29877892\">",
"      Guidelines from expert groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      RECURRENT OR PERSISTENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Relapse after surgery alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Relapse after adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      LATE EFFECTS OF CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Gonadal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Secondary malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      DIAGNOSIS AND TREATMENT IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3197\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3197|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/43/15038\" title=\"table 1\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/4/24653\" title=\"table 2\">",
"      Ovarian tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/24/43404\" title=\"table 3\">",
"      Outcomes chemo nondysgerm OGCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/2/14382\" title=\"table 4\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/19/20795\" title=\"table 5\">",
"      Outcome surveil IA dysgerminoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/58/940\" title=\"table 6\">",
"      Treatment recommend ovar GCT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19287?source=related_link\">",
"      Chemotherapy of ovarian cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/15/25847?source=related_link\">",
"      Epithelial ovarian cancer: Second look surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26070?source=related_link\">",
"      Management of stage I nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14425?source=related_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9943?source=related_link\">",
"      Posttreatment follow-up for men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24852?source=related_link\">",
"      Risk stratification of metastatic testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38425?source=related_link\">",
"      Surgical management of advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/56/2954?source=related_link\">",
"      Treatment of relapsed and refractory testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_24_33163="Nebulizer performance";
var content_f32_24_33163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors affecting aerosol delivery by nebulizer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Technical Factors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mechanism and manufacturer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Flow rate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fill volume",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Solution characteristics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Characteristics of driving gas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Designs to enhance output",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Continuous versus intermittent delivery",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Patient Factors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Breathing pattern",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nose versus mouth breathing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Artificial airway",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Airway obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Positive pressure level",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33163=[""].join("\n");
var outline_f32_24_33163=null;
var title_f32_24_33164="Atomic and molecular weights";
var content_f32_24_33164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F50668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F50668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Atomic and molecular weight",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Substance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symbol or formula",
"       </td>",
"       <td class=\"subtitle1\">",
"        Atomic or molecular weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium ion",
"       </td>",
"       <td>",
"        Ca2+",
"       </td>",
"       <td>",
"        40.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbon",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloride ion",
"       </td>",
"       <td>",
"        Cl-",
"       </td>",
"       <td>",
"        35.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrogen ion",
"       </td>",
"       <td>",
"        H+",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium ion",
"       </td>",
"       <td>",
"        Mg2+",
"       </td>",
"       <td>",
"        24.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrogen",
"       </td>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxygen",
"       </td>",
"       <td>",
"        O",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphorus",
"       </td>",
"       <td>",
"        P",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium ion",
"       </td>",
"       <td>",
"        K+",
"       </td>",
"       <td>",
"        39.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium ion",
"       </td>",
"       <td>",
"        Na+",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfur",
"       </td>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        32.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ammonia",
"       </td>",
"       <td>",
"        NH3",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ammonium ion",
"       </td>",
"       <td>",
"        NH4+",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bicarbonate ion",
"       </td>",
"       <td>",
"        HCO3-",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbon dioxide",
"       </td>",
"       <td>",
"        CO2",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose",
"       </td>",
"       <td>",
"        C(6)H(12)O(6)",
"       </td>",
"       <td>",
"        180",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phosphate ion",
"       </td>",
"       <td>",
"        PO4(3-)",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfate ion",
"       </td>",
"       <td>",
"        SO4(2-)",
"       </td>",
"       <td>",
"        96.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urea",
"       </td>",
"       <td>",
"        NH2CONH2",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water",
"       </td>",
"       <td>",
"        H2O",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Atomic and molecular weights of physiologically important substances.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33164=[""].join("\n");
var outline_f32_24_33164=null;
var title_f32_24_33165="Doses drugs asthma attack";
var content_f32_24_33165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doses of drugs for asthma exacerbations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Medication",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Dosages",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Child dose, &lt;12 years",
"      </td>",
"      <td class=\"subtitle2\">",
"       Adult dose, &ge;12 years",
"      </td>",
"      <td class=\"subtitle2\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Inhaled short-acting beta",
"       <sub>",
"        2",
"       </sub>",
"       -agonists (SABA)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Albuterol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"4\">",
"       Nebulizer solution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       <p>",
"        0.63 mg/3 mL,",
"       </p>",
"       <p>",
"        1.25 mg/3 mL,",
"       </p>",
"       <p>",
"        2.5 mg/3 mL,",
"       </p>",
"       <p>",
"        5.0 mg/mL",
"       </p>",
"      </td>",
"      <td class=\"sublist_other\">",
"       0.15 mg/kg (minimum dose 2.5 mg) every 20 minutes for 3 doses then 0.15-0.3 mg/kg up to 10 mg every 1-4 hours as needed, or 0.5 mg/kg/hour by continuous nebulization.",
"      </td>",
"      <td class=\"sublist_other\">",
"       2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours as needed, or 10-15 mg/hour continuously.",
"      </td>",
"      <td class=\"sublist_other\">",
"       Only selective beta",
"       <sub>",
"        2",
"       </sub>",
"       -agonists are recommended. For optimal delivery, dilute aerosols to minimum of 3 mL at gas flow of 6-8 L/min. Use large volume nebulizers for continuous administration. May mix with ipratropium nebulizer solution.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"4\">",
"       Metered-dose inhaler (MDI)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       90 mcg/puff",
"      </td>",
"      <td class=\"sublist_other\">",
"       4-8 puffs every 20 minutes for 3 doses, then every 1-4 hours as needed. Use valved holding chamber (VHC); add mask in children &lt;4 years.",
"      </td>",
"      <td class=\"sublist_other\">",
"       4-8 puffs every 20 minutes up to 4 hours, then every 1-4 hours as needed.",
"      </td>",
"      <td class=\"sublist_other\">",
"       In mild-to-moderate exacerbations, MDI plus VHC is as effective as nebulized therapy with appropriate administration technique and coaching by trained personnel.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Bitolterol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"4\">",
"       Nebulizer solution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       2 mg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       See albuterol dose; thought to be half as potent as albuterol on mg basis.",
"      </td>",
"      <td class=\"sublist_other\">",
"       See albuterol dose.",
"      </td>",
"      <td class=\"sublist_other\">",
"       Has not been studied in severe asthma exacerbations. Do not mix with other drugs.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"4\">",
"       MDI",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       370 mcg/puff",
"      </td>",
"      <td class=\"sublist_other\">",
"       See albuterol MDI dose.",
"      </td>",
"      <td class=\"sublist_other\">",
"       See albuterol MDI dose.",
"      </td>",
"      <td class=\"sublist_other\">",
"       Has not been studied in severe asthma exacerbations.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Levalbuterol (R-albuterol)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"4\">",
"       Nebulizer solution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       <p>",
"        0.63 mg/3 mL,",
"       </p>",
"       <p>",
"        1.25 mg/0.5 mL,",
"       </p>",
"       <p>",
"        1.25 mg/3 mL",
"       </p>",
"      </td>",
"      <td class=\"sublist_other\">",
"       0.075 mg/kg (minimum dose 1.25 mg) every 20 minutes for 3 doses, then 0.075-0.15 mg/kg up to 5 mg every 1-4 hours as needed.",
"      </td>",
"      <td class=\"sublist_other\">",
"       1.25-2.5 mg every 20 minutes for 3 doses, then 1.25-5 mg every 1-4 hours as needed.",
"      </td>",
"      <td class=\"sublist_other\" rowspan=\"3\">",
"       Levalbuterol administered in one-half the mg dose of albuterol provides comparable efficacy and safety. Has not been evaluated by continuous nebulization.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\">",
"       MDI",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       45 mcg/puff",
"      </td>",
"      <td class=\"sublist_other\">",
"       See albuterol MDI dose.",
"      </td>",
"      <td class=\"sublist_other\">",
"       See albuterol MDI dose.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Pirbuterol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"4\">",
"       MDI",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       200 mcg/puff",
"      </td>",
"      <td class=\"sublist_other\">",
"       See albuterol MDI dose; thought to be half as potent as albuterol on a mg basis.",
"      </td>",
"      <td class=\"sublist_other\">",
"       See albuterol MDI dose.",
"      </td>",
"      <td class=\"sublist_other\">",
"       Has not been studied in severe asthma exacerbations.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Systemic (injected) beta",
"       <sub>",
"        2",
"       </sub>",
"       -agonists",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Epinephrine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1:1000 (1 mg/mL)",
"      </td>",
"      <td class=\"sublist_other\">",
"       0.01 mg/kg up to 0.3-0.5 mg every 20 minutes for 3 doses (administered subcutaneously).",
"      </td>",
"      <td class=\"sublist_other\">",
"       0.3-0.5 mg every 20 minutes for 3 doses (administered subcutaneously)",
"      </td>",
"      <td class=\"sublist_other\">",
"       No proven advantage of systemic therapy over aerosol.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Terbutaline",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       1 mg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       0.01 mg/kg every 20 minutes for 3 doses then every 2-6 hours as needed (administered subcutaneously).",
"      </td>",
"      <td class=\"sublist_other\">",
"       0.25 mg every 20 minutes for 3 doses (administered subcutaneously).",
"      </td>",
"      <td class=\"sublist_other\">",
"       No proven advantage of systemic therapy over aerosol.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: US Department of Health and Human Services. Expert panel report 3: Guidelines for the diagnosis and management of asthma. NIH Publication No. 07-4051. August 2007. p.386.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33165=[""].join("\n");
var outline_f32_24_33165=null;
var title_f32_24_33166="Mechanisms for urate reabsorption by the proximal tubule";
var content_f32_24_33166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Mechanisms for urate reabsorption by the proximal tubule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 386px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sodium-dependent anion transport by SLC5A8 and SLC5A12 increases intracellular concentrations of anions that exchange with luminal urate (URAT1/OAT10/OAT4). GLUT9 is the presumptive exit pathway for urate at the basolateral membrane but may also traffic to the apical membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33166=[""].join("\n");
var outline_f32_24_33166=null;
var title_f32_24_33167="Postop CBD stricture resolved";
var content_f32_24_33167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cholecystectomy-associated stricture following stenting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiogram twelve months after stent removal demonstrates near complete stricture resolution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_24_33167=[""].join("\n");
var outline_f32_24_33167=null;
